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The mechanistic target of rapamycin (mTOR) perceives and integrates various 
extracellular and intracellular signals and regulates cellular growth and homeostasis. 
The evolutionary conserved serine/threonine kinase can form two functionally and 
structurally distinct complexes, mTORC1 and mTORC2. Regulation of these 
complexes occurs through levels of glucose and amino acids, energy levels, 
hormones, growth factors and neurotransmitters. mTOR regulates mRNA translation, 
lipid biosynthesis, auto- and mitophagy, and lysosome biogenesis. Signalling 
pathways that are regulated by mTOR are involved in integrated processes of 
neuronal development, synapse formation and plasticity, memory and cognition. 
Brain-related alterations in mTOR signalling are connected to pathological conditions 
like epilepsy, depression, autism, schizophrenia, Alzheimer's and Parkinson's 
disease. 
While some aspects of mTOR signalling, like the regulation of mRNA translation, are 
well understood, others remain loosely defined. We have therefore developed two 
quantitative optical tools that analyse the endogenous activity of mTORC1 and 
mTORC2. We use antibodies in ratiometric FRET assays to quantify activity states of 
both mTOR complexes. The application of these assays to neurons from MeCP2-KO 
mice, a mouse model of Rett syndrome, a severe neurodevelopmental disorder, 
confirmed a reduced mTORC1 activity in MeCP2-KO neurons. These experiments 
also suggested a neuron-specific reduction of mTORC1 activity as well as a general 
reduction in mTORC2 signalling. These impairments may represent a reason for the 
observed reduced number of synapses in Rett syndrome. 
The interaction of mTOR with gephyrin, the major organiser of the inhibitory 
postsynapse, has been described in the past. This interaction has the potential to 
regulate inhibitory synapse formation and plasticity by localised protein translation at 
the inhibitory postsynapse. We developed a FRET assay that confirmed the 
interaction between mTOR and gephyrin. We found that gephyrin exclusively 
interacted with mTORC1, and that serine 270 of gephyrin is an important determinant 
of this interaction. Serine 270 is a target of GSK-3β and CDK5 in the brain, which 




3β/CDK5 mediated recruitment of mTORC1 to the postsynaptic gephyrin network 
may represent a mechanism for regulating synapse formation and plasticity.  
In order to organise the inhibitory postsynapse, gephyrin forms a 2-dimensional 
network underneath the synaptic membrane. Synaptic adhesion molecules and 
inhibitory neurotransmitter receptors interact with the gephyrin network and are 
organised by it. We developed two FRET assays that measure the formation of the 
gephyrin network. We demonstrate that inhibition of mTORC1 promotes the 
formation of the gephyrin network at GABAergic postsynaptic sites. This may 






Das Protein mechanistic target of rapamycin (mTOR) empfängt und integriert 
vielfältige extrazelluläre sowie intrazelluläre Signale und reguliert zelluläres 
Wachstum und Homöostase. Es handelt sich um eine evolutionär konservierte 
Serin/Threonin Kinase, die zwei strukturell und funktionell unterschiedliche Komplexe 
bildet, mTORC1 und mTORC2. Die Regulation dieser Komplexe erfolgt durch 
Nährstoffe, wie Glukose und Aminosäuren, den Energiegehalt der Zelle, Hormone, 
Wachstumsfaktoren sowie Neurotransmitter. mTOR reguliert die mRNS-Translation, 
die Lipidbiosynthese, die Auto-/Mitophagie und die Lysosombildung. Signalwege die 
durch mTOR reguliert werden umfassen integrierte Prozesse wie die neuronale 
Entwicklung, Synapsenbildung und -plastizität, Erinnerung und Wahrnehmung. 
Veränderungen der mTOR Signalgebung im Gehirn stehen mit pathologischen 
Zuständen wie Epilepsie, Depressionen, Autismus, Schizzophrenie, Alzheimer und 
der Parkinson Krankheit in Verbindung.  
Während einige Aspekte der mTOR Signalgebung gut bestimmt sind, sind andere 
kaum definiert. Wir haben deshalb quantitative optische Werkzeuge entwickelt die 
die Analyse der mTORC1- sowie mTORC2-Aktivität erlauben. Wir benutzen 
Antikörper in ratiometrischen FRET-Analyse0 um die Aktivitätszustände von mTOR 
zu messen. Die Anwendung dieser Analysen in Neuronen aus MeCP2 knockout 
Mäusen, einem Mausmodell des Rett-Syndroms, konnten bestätigen, das die mTOR-
Aktivität in den Gehirnen dieser Mäuse reduziert war. Diese Experimente deuteten 
außerdem eine neuron-spezifische Reduzierung der mTORC1-Aktivität, sowie eine 
allgemeine Verringerung der mTORC2-Aktivität an. Diese Veränderungen könnten 
einen Grund für die beobachtete reduzierte Anzahl von Synapsen bei Rett Mäusen 
darstellen. 
Die Interaktion von mTOR und Gephyrin, dem wichtigsten Organisator der 
inhibierenden Postsynapse, wurde bereits in der Vergangenheit beschrieben. Diese 
Interaktion hat das Potenzial, die Bildung und Plastizität inhibitorischer Synapsen 
durch lokale Proteintranslation zu bestimmen. Wir entwickelten eine FRET Analyse 
welche die Interaktion zwischen mTOR und Gephyrin auf Einzelzellniveau zeigt und 
quantifiziert. Wir konnten zeigen, das Gephyrin exklusiv mit mTORC1 interagiert und 




Um die hemmende Postsynapse zu organisieren, bildet Gephyrin ein 
zweidimensionales Netzwerk unter der postsynaptischen Membran. Synaptische 
Adhäsionsmoleküle und hemmende Neurotransmitter-Rezeptoren interagieren mit 
diesem Netzwerk. Wir entwickelten zwei FRET-Analysen, welche die Bildung des 
Netzwerkes quantitativ bestimmen können. Damit konnten wir zeigen, das die 
Vernetzung durch Hemmung von mTORC1 befördert wird. Dies stellt möglicherweise 





1 Introduction  
1.1 Inhibitory neurotransmission 
Neuronal inhibition has two major functions: interrupting activity and the restricting 
activation patterns in time and space, providing the necessary autonomy for 
neighbouring excitatory cells and guaranteeing their functional diversity. For this 
purpose the brain contains multiple classes of specialized interneurons that 
selectively innervate excitatory neurons and other interneurons by forming inhibitory 
synapses.  
Inhibitory synapses are basic structures required for information-processing within 
neural circuits. Their spatial arrangement and temporal activation sequence allows 
for sophisticated analysis of sensory inputs on all organizational levels of the nervous 
system. 
In the central nervous system fast synaptic inhibition is facilitated by two 
neurotransmitters: GABA and glycine. These are released from presynaptic active 
zones of inhibitory interneurons onto membrane specialisations of their target cells, 
the inhibitory postsynapse. Simplified, the inhibitory postsynapse contains 
neurotransmitter receptors, synaptic adhesion molecules, scaffolding molecules, and 
accessory signalling molecules that relay inhibitory inputs onto target cells. 
Synaptic release of GABA and glycine activates ligand-gated chloride channels, like 
type A GABA (GABAA receptor) and glycine receptor (GlyR). Type B GABA receptors 
belong to the class of G protein-coupled receptors that activate potassium channels, 
and mediate slow inhibition. Inhibitory neurotransmitter receptors are anchored and 
clustered at the postsynaptic specialisation, a scaffolding structure underneath the 
postsynaptic membrane which contains the scaffolding molecule Gephyrin. Gephyrin 
also interacts with multiple classes of signalling molecules and undergoes complex 
post-translational modifications, making it a major regulator of synaptic inhibition in 




1.2 Gephyrin  
1.2.1 Structure and function 
Gephyrin is a highly conserved protein that is widely expressed in vertebrate tissues 
where it plays a multifunctional role (Ogino et al. 2011; Nawrotzki et al. 2012). In non-
neuronal cells, gephyrin's primary function is the synthesis of molybdenum cofactor 
(Moco), a co-enzyme involved in catalysing redox reactions (Stallmeyer et al. 1999; 
Schwarz et al. 2009). It's other function is specific to neurons as it structurally and 
functionally organizes the inhibitory post-synapse (Fritschy et al. 2008; Tretter et al. 
2012). Gephyrin was first isolated from glycine receptor preparations, where it was 
also bound to polymerized tubulin (Pfeiffer et al. 1982). Supposedly its function was 
to bridge neurotransmitter receptors and the cytoskeleton (Kirsch et al. 1991). 
Today it is widely accepted that gephyrin's role at the inhibitory postsynapse is not 
restricted to this structural function as a scaffolding protein. Gephyrin also represents 
as a major signalling hub for various inputs involved in synapse formation, 
modulation, synaptic plasticity, and transport processes, making it a potential master 
regulator of the inhibitory synaptic transmission (Tyagarajan and Fritschy 2014). 
Gephyrin is a 93 kDa protein comprising of 3 domains, an N-terminal G-domain 
followed by a flexible linker domain also referred to as the C-domain, and an E-
domain at the C-terminus. Sequence analysis revealed a high degree of homology 
with two bacterial enzymes, MogA and MoeA, both involved in consecutive steps of 
aforementioned molybdenum cofactor biosynthesis. The gephyrin gene seems to 
have evolved by fusion of the MogA and the MoeA genes (Fritschy et al. 2008). In 
mammals gephyrin is highly abundant in liver, kidney and other non-neuronal tissues, 
where it is believed to catalyse molybdenum cofactor synthesis independent of its 
aggregation state and neuronal function (Schwarz et al. 2009). In the nervous system 
molybdenum cofactor synthesis seems to be restricted to astrocytes and the 
significance of Moco synthesis for synaptic function yet to be demonstrated 
(Smolinsky et al. 2008). 
Dual-label electron microscopy and fluorescence microscopy revealed that gephyrin 
immunoreactive punctae, termed "clusters", were found to be between 50 and 




very high local concentrations (Triller et al. 1985; Sassoe-Pognetto et al. 1995; 
Sassoè-Pognetto et al. 2000, Lardi-Studler et al. 2007). 
Analysis of the self-aggregation properties of gephyrin showed that isolated G-
domains spontaneously form trimers while isolated E-domains form dimers (Schwarz 
et al. 2001; Sola et al. 2004). The binding site for the glycine receptor has been 
mapped to the E-domain (Schrader et al. 2004; Kim et al. 2006). These observations 
integrate into a model in which three gephyrin molecules form a star-shaped trimer 
via their G-domains. The 3 outwardly oriented E-domains of a gephyrin trimer 
molecule may recruit other gephyrin trimers building up a hexagonal lattice structure 
that binds to glycine- or GABAA receptors (Figure 1A). A recent report points out that 
the C-domain may play an important role in regulating gephyrin clustering. Because 
of its unstructured folding as well as interactions with the G and the E domain, 
gephyrin may be able to occupy different states of extension which could provide 
structural flexibility within the scaffold (Sander et al. 2013) (Figure 1B). 
The so called lattice model of gephyrin clustering is based purely on observations 
made with single isolated protein domains expressed in recombinant expression 
systems in which no mammalian post-translational modifications are implemented. In 
vitro gephyrin has been shown to undergo extensive post-translational modifications 
like phosphorylation and acetylation. It is believed that these modifications are 
significant for synaptic localization and aggregation of gephyrin but may also play a 
role in synaptic signalling. Accordingly, the lattice model was called into question 
after it was reported that full-length gephyrin expressed in vertebrate cells shows 
very different aggregation properties with a stacked double-trimer being the 
predominant form of gephyrin aggregates. In the alternate stacked trimer model, 
gephyrin forms trimers via the G or G and C domain and these trimers are then 
formed into stacks via an E-domain interaction (Figure 1C and 1D). 
In both models, the E-domains point outwardly and allow the interaction with glycine 
receptors, neuroligin 2 (NL2) or collybistin (CB) However, only the hexagonal lattice 
model is consistent with the observed 1:1 ratio of gephyrin to bound receptors at 











1.2.2 Gephyrin and postsynaptic receptors 
Glycine- and GABAA-receptors are pentameric chloride channels that together with 
nicotinic acetylcholine receptors and serotonin receptors make up a superfamily of 
Cys-loop ligand-gated ion channels. 
Glycine receptors are comprised of 5 subunits, α1-α4 and β, encoded by 5 genes. 
These subunits assemble into homomeric (only α-subunits) or heteromeric (α- and β-
subunits) receptors which colocalise perfectly with gephyrin when visualized by 
immunofluorescence (Triller et al. 1985). The high spatial correlation is caused by the 
high binding affinity between gephyrin and the intracellular loop of the β-subunit 
(Kirsch et al. 1991; Meyer et al. 1995; Dumoulin 2009). This binding affinity is high 
enough for gephyrin to bind to glycine receptor-containing transport vesicles leading 
to a co-transport of both molecules within dendrites. Binding of gephyrin to dynein 
motor proteins forms a GlyR-gephyrin-dynein transport complex. Activity dependend 
polyglutamyolation of tubulin contributes to the dynamic regulation of the glycinergic 
postsynapse by the transport rate of GlyR-gephyrin aggregates (Hanus 2004; Maas 
et al. 2006). 
GABAA-receptors show extensive subunit heterogeneity with 19 genes encoding for 
subunits α1-α6, β1-β3, γ1-γ3, δ, ε,π, θ and ρ1-ρ3. A full receptor pentamer is usually 
assembled from at least 3 different classes of subunits, for example α-, β- and γ- or 
α-, β- and δ-subunits (Barnard et al. 1998). Only the subset of α1, α2 or α3 subunits 
along with γ2 subunit combinations colocalises with gephyrin clusters at inhibitory 
postsynapses (Tretter et al. 2008; Mukherjee et al. 2011; Tretter et al. 2011; 
Kowalczyk et al. 2013). By contrast α4, and α5 and δ-subunits containing GABAA-
receptors are mainly localised extrasynapticly and do not colocalise with gephyrin. 
Targeted deletion of the γ2-subunit reduces the postsynaptic gephyrin cluster 
formation although γ2 does not directly interact with gephyrin. This indirect effect may 
be due to reduced cell surface expression of γ2-deficient GABAA-receptors (Günther 
et al. 1995).  
The role of gephyrin in postsynaptic clustering of GABAA-receptors is not entirely 
clear. GPHN knockout (KO) mice show impeded but not abolished GABAA-receptors 
clustering depending on the neuronal subtype (Fischer et al. 2000; Kneussel et al. 
2001; Levi 2004). However, in GABAergic postsynapses, gephyrin clustering 




certain subtypes which have substantial influence on the molecular composition and 
function of the inhibitory postsynapse (Fritschy 2006; Kralic et al. 2006; Peden et al. 
2008). 
The structural heterogeneity of GABAA-receptors seems to provide variability to the 
molecular and functional properties of GABAergic synapses (Wu et al. 2012). In 
addition, GABAergic synapses are equipped with distinct signalling complexes that 
are specific to subcellular compartments or neuronal subtypes. For example the 
dystrophin-glycoprotein complex (DGC) which regulates postsynaptic anchoring of a 
selective subset of GABAA-receptors, independently of gephyrin in cortical and 
cerebellar synapses (Kneussel and Betz 2000). 
 
1.3 Regulators of gephyrin clustering 
1.3.1 Neuroligins 
Neuroligins are postsynaptic adhesion molecules that, together with their presynaptic 
counterparts the neurexins, play a fundamental role in excitatory and inhibitory 
synapse formation and function. Neuroligins are expressed in 4 isoforms, neuroligin-
1 to -4 (NL 1-4) (Hu et al. 2015). The presynaptic neurexins bind to all neuroligin 
isoforms, but, in contrast to neurexins, neuroligins are specifically localized to 
particular synapses. NL1 is only present in excitatory synapses (Chubykin et al. 
2007) while NL2 and 4 are present at glycinergic and GABAergic synapses 
(Varoqueaux et al. 2004; Hoon et al. 2011). NL3 is present at both types of synapses 
(Budreck and Scheiffele 2007). NL2 is the only synaptic adhesion molecule known to 
bind gephyrin in GABAergic synapses. It is therefore believed to facilitate gephyrin 
and GABAA-receptors clustering in nascent GABAergic postsynapses (Poulopoulos 
et al. 2009).  
The targeted deletion of single NL isoforms was not sufficient to unveil the specific 
function of NL probably due to compensatory effects of NL1 and NL3 and NL2, NL4 
and NL3. 
NL2-deficient mice display region-specific alterations of GABAergic synapses. These 




the hippocampus and the dentate gyrus, perisomatic but not dendritic GABAA-
receptors and gephyrin clusters are lost (Gibson et al. 2009; Jedlicka et al. 2011). 
The major behavioural aberration observed in these mice is increased anxiety, which 
is compatible with reduced inhibitory transmission in brain regions that regulate 
emotional behaviour (Blundell et al. 2009). 
 
1.3.2 Collybistin 
Collybistin has been found to interact with gephyrin and is able to translocate 
gephyrin to the plasma membrane in non-neuronal cells (Kins et al. 2000). It is a 
neuron-specific guanosine triphosphate exchange factor (GEF) for the cell division 
control protein 42 (CDC42) (Xiang et al. 2006). It belongs to the DBL family of GEFs. 
All members of this family activate small GTPases of the Rho family and comprise of 
three domains that align in a fixed order: an N-terminal type 3 Src-homology domain 
(SH3-), followed by a DBL homology (DH-) domain which possesses GEF activity 
and a C-terminal pleckstrin homology (PH-) domain (Miller et al. 2013). 
Collybistin pre-mRNA is coded by the gene Arhgef9 and is subject to extensive 
alternative splicing, which gives rise to three isoforms (CB1-CB3) that differ in their 
C-terminus. Further splicing generates 2 versions of each isoform with or without the 
N-terminal SH3 domain. The SH3 domain can bind to the DH domain rendering 
collybistin inactive by blocking its catalytic centre. It is assumed that the autoinhibition 
is released by binding of collybistin to NL2 via the SH3 domain (Soykan et al. 2014). 
The functional relevance of the known 6 isoforms of collybistin is not yet determined, 
but the expression of different isoforms in neurons points toward non-overlapping 
functions (Chiou et al. 2011; Tyagarajan et al. 2011; Körber et al. 2012; Fritschy et al. 
2012). 
In non-neuronal cells, only the SH3 domain-deficient splice variant of CB2 is capable 
to translocate and activate gephyrin at the plasma membrane (Kins et al. 2000). To 
do so, collybistin binds gephyrin at the C-terminal collybistin binding domain (CBD) at 
a binding site that is overlapping with the binding site for GABAA-receptor α2 and α3 




collybistin's DH domain which might interfere with collybistin's ability to activate 
CDC42 (Xiang et al. 2006). 
The Arhgef9 null mouse revealed that collybistin is not required for gephyrin 
clustering or glycine receptor co-clustering at glycinergic synapses. More importantly, 
this mouse model revealed a remarkable cell- and synapse-specific heterogeneity of 
gephyrin clustering phenotypes in the GABAergic system. In Purkinje cells, gephyrin- 
but not GABAA-receptor clustering was disrupted while in hippocampal and cortical 
pyramidal cells gephyrin and GABAA-receptor clustering was impaired and 
GABAergic transmission was reduced (Papadopoulos et al. 2008). Behaviourally, the 
Arhgef9 null mice showed increased signs of anxiety and impaired spatial learning 
compatible with the reduced inhibitory neurotransmission phenotype. In agreement 
with this mouse model, a human case of Arhgef9 gene deletion was reported to show 
a severely deficient adaptive behaviour, moderate to mild autism and frequent 
epileptic discharges (Machado et al. 2015). 
 
1.4 Gephyrin clustering 
1.4.1 The receptor activation model 
The receptor activation model aims to explain the role of gephyrin in glycine- and 
GABAA-receptor clustering at postsynaptic sites. In immature neurons, an initial 
release of presynaptic GABA or glycine induces membrane depolarisation due to 
chloride efflux. In immature neurons the chloride concentration is higher inside than 
outside so that a change in chloride permeability leads to a depolarisation instead of 
a further polarisation like in mature neurons (Ben-Ari et al., 1989). This depolarisation 
leads to calcium influx through voltage-dependent calcium channels which induces 
the membrane apposition of GlyR and hence the clustering of gephyrin (Kneussel 
and Betz 2000). Clustered gephyrin binds via adaptor molecules to the actin 
cytoskeleton and to polymerised tubulin and starts to immobilise more glycine and 
GABA receptors. Furthermore calcium influx induces the release of brain derived 
neurotrophic factor (BDNF) which activates phosphatidylinositol 3 kinase (PI3K) 
which promotes the production of phosphatidylinositol-3,4,5-triphosphate. The latter 




The receptor activation model does not explain why constant GABAA-receptor 
antagonism does not prevent the formation of GABAergic synapses in vitro. 
Therefore the key role for activating gephyrin clustering was attributed to collybistin 
rather than receptor activation. Until today no other model has replaced the receptor 
activation model and it is not known which synaptic adhesion molecule triggers 
gephyrin clustering. Nevertheless, the ability of gephyrin to bind transsynaptic 
adhesion molecules in combination with their synapse-specific segregation raises the 
question if gephyrin is involved in determining neurotransmitter specificity by 
assembling a certain type of receptors. 
 
1.4.1.1 Gephyrin clustering at glycinergic synapses 
The Arhgef9 knock out mouse demonstrated that collybistin is dispensable for 
gephyrin clustering at glycinergic synapses as these mice do not exhibit glycinergic 
synapse dysfunction and are viable and fertile (Papadopoulos et al. 2008). 
It is therefore assumed that the observed co-transport of gephyrin on glycine-
receptor carrying transport vesicles is the foundation of gephyrin clustering in 
glycinergic synapses. After gephyrin-decorated glycine receptors appear on the cell 
surface, they diffuse laterally within the plasma membrane until they reach a synaptic 
spot where gephyrin starts to cluster upon binding to synaptic adhesion molecules 
(Dumoulin 2009; Calamai et al. 2009). The clustering and accumulation is regulated 
by several factors. For example integrin β1 and β3 have been shown to regulate the 
postsynaptic accumulation of glycine receptors and the binding to the gephyrin 
scaffold (Charrier et al. 2006). Protein kinase C was reported to influence receptor 
diffusion and gephyrin interaction (Specht et al. 2013). And ultimately, heat shock 
cognate protein of 70 kDa can regulate gephyrin clustering without influencing 
glycine receptor accumulation (Machado et al. 2011). 
 
1.4.1.2 Gephyrin clustering at GABAergic synapses 
A model for gephyrin clustering at GABAergic synapses is based on the observation 




binding to neuroligin 2 activates collybistin which in turn recruits gephyrin to the 
plasma membrane. Clustered gephyrin then immobilizes GABAA-receptors at 
nascent GABAergic synapses.  
An alternative model postulates that, first, a trimeric complex of GABAA-receptor α2-
subunit, collybistin and gephyrin forms which disinhibits collybistin and nucleates the 
formation of inhibitory postsynapses. Both models require collybistin activation as a 
prerequisite for gephyrin clustering. Consequently, both models fail to explain the 
heterogeneity of gephyrin clustering phenotypes in the Arhgef9 null mouse. It will 
therefore be necessary to take the molecular heterogeneity of receptors, synapses 
and regions into account in order to understand the complexity of gephyrin clustering 














1.4.2 Gephyrin phosphorylation in GABAergic synapse plasticity  
1.4.2.1 GSK-3β and CDK5 dependent phosphorylation of serine 270 
Gephyrin has been identified as a highly phosphorylated protein very early on 
(Langosh et al., 1992), but the functional relevance of the phosphorylation has long 
been neglected for its mere structural role. Gephyrin harbours 22 serine- (S) and 
threonine- (T) phosphorylation motives in its regulatory C-domain (Sander et al. 
2013). It also represents the most flexible and accessible part in the molecule and is 
therefore the most likely target for posttranslational modifications (Herweg and 
Schwarz 2012). Phosphorylation could lead to conformational changes of the C-
domain relative to the adjacent G- and E-domains, and alter the clustering properties 
of the molecule. An interaction of the C-domain with the E-domain as well as the G-
domain was reported to regulate different states of extension of gephyrin which 
represents a potential mechanism of regulating gephyrin clustering (Sander et al. 
2013). 
The first identified phosphorylation site that is targeted by a specific kinase was 
S270, phosphorylated by glycogen synthase kinase 3 β (GSK-3β) (Tyagarajan et al. 
2011). In the brain GSK-3β is involved in developmental processes like 
neurogenesis, polarization and axon outgrowth (Hur and Zhou 2010). Alanine (A) 
exchange mutations of S270 produces a phenotype with supernumerary gephyrin 
clusters and GABAergic synapses which leads to enhanced frequencies of miniature 
inhibitory post-synaptic currents (mIPSC). Pharmacological blockage of GSK-3β 
activity using LiCl shows a similar effect. In the brain, protein kinase Akt inhibits GSK-
3β which potentially connects neuronal activity by calcium-induced activation of the 
BDNF-TrkB-Akt signalling pathway to posttranslational modfication of gephyrin at 
S270. The reduced phosphorylation seems to stimulate the formation of new 
inhibitory synapses. Alanine exchange mutations as well as inhibition of GSK-3β, 
recapitulates this effect.  
In excitatory synapses, the link between synaptic activity and protein translation is 
well established. It is a process involved in long term plasticity that connects NMDA-
receptor activity and calcium influx to BDNF autocrine activation of the Akt/mTOR/S6 




A potential mechanism for inhibitory synapses has been suggested by Sabatini and 
colleagues (1999). They describe the interaction between mechanistic target of 
rapamycin (mTOR), the major regulator of cap-dependent protein translation, and 
gephyrin. The authors also demonstrate that mutants of mTOR that were unable to 
bind to gephyrin also fail to activate downstream targets responsible for mRNA 
translation initiation (Sabatini et al. 1999). The link between mTOR and gephyrin still 
lacks confirmation in inhibitory synapses and it would be interesting if this indicated 
connection could be further substantiated. 
A second serine-threonine kinase that is capable of phosphorylating gephyrin at 
S270 is cyclin-dependent kinase 5 (CDK5). CDK5 is implicated in several aspects of 
neurodevelopment and neuronal function like neuronal migration, differentiation, 
synaptic function, homeostasis and plasticity (Su and Tsai 2011). In excitatory 
synapses, CDK5 regulates synaptic plasticity by 3 different mechanisms, 1: it 
mediates changes in NMDA receptor conductance by phosphorylation of receptor 
subunits (Li et al. 2001); 2: it can reduce the number of NMDA receptors by calpain-
dependent proteolysis (Hawasli et al. 2007) and 3: it can activate NMDA receptor 
internalization by phosphorylating PSD-95, inducing LTD (Morabito 2004). In 
inhibitory synapses CDK5 seems to cooperate with collybistin. Collybistin is known to 
regulate gephyrin clustering which suggests that phosphorylation of S270 depends 
on clustered gephyrin (Kuhse et al. 2012). 
 
1.4.2.2 ERK1/2 dependent phosphorylation of serine 268 
The mitogen-activated protein kinase (MAPK) cascade that activates extracellular 
signal-regulated protein kinases-1 and -2 (ERK1 and ERK2) plays a key role in the 
control of synaptic plasticity in the adult brain. It seems to be essential for neuronal 
transcriptional events and might regulate synaptic targets directly to control plasticity. 
The classical way of ERK activation is via receptor tyrosine kinases, adaptor protein 
binding followed by alterations in the balance between the activities of Ras-GEFs and 
Ras-GAPs. In neurons, this pathway operates in response to neurotrophic factors. 
However, ERK activation by membrane depolarization or glutamatergic signalling 
requires calcium influx facilitated by NMDA receptors or voltage-gated calcium 




LTP. It enhances functional properties of glutamate receptors by affecting the 
trafficking, structural remodelling of activated spines and local protein translation 
(Thomas and Huganir 2004). 
In GABAergic synapses, activated ERK 1/2 phosphorylates gephyrin at S268. 
Phosphorylation of S268 seems to limit the size of gephyrin clusters and reduces the 
amplitude and frequency of mIPSCs in vitro (Tyagarajan et al. 2013). Moreover, 
phosphorylation of S268 seems to function in synergy with phosphorylation at the 
neighbouring S270 to reduce size and number of inhibitory synapses. 
 
1.4.2.3 Peptidyl-prolyl cis-trans isomerase Pin-1 
Protein phosphorylations at serine and threonine residues that are followed by a 
proline residue are called proline-directed phosphorylations. They often lead to 
conformational changes that are not solely caused the phosphorylation event itself. 
Instead, they require mediation by chaperone molecules called peptidyl-prolyl cis-
trans isomerases (PPIases). Pin1 and its homologs are the only known isomerases 
being able to catalyse isomerisation of already phosphorylated amino acid side 
chains (Yaffe 1997). These proteins are able to catalyse cis to trans or trans to cis 
isomerisations in order to create targeting sites for conformation selective pro-
directed kinases and phosphatases (Weiwad et al. 2000; Zhou 2000). Neuronal 
targets of Pin-1 are tau, amyloid-ß protein precursor (APP), α-synuclein and 
neurofilaments which have implications in amyotrophic lateral sclerosis, Parkinson's 
and Alzheimer's disease (Rudrabhatla and Pant 2010; Lee 2015). Beyond these 
implications, Pin-1 is involved in apoptosis required for neurodevelopmental 
processes and in forms of long-term synaptic plasticity at excitatory synapses 
(Becker and Bonni 2006; Westmark et al. 2010). 
In gephyrin, three serine residues have been identified to recruit Pin-1: S188, S194 
and S200. Pin1-driven conformational changes have been shown to affect the affinity 
of GlyR β-subunit to gephyrin (Moretto Zita et al. 2007). Hippocampal neurons 
derived from Pin-1 KO mice show less glycine receptor immunoreactive punctae as 
well as reduced amplitudes of glycine-evoked currents. Hence, Pin-1-dependent 
conformational changes following phosphorylation events represent a potential 




Pin-1 activity in GABAergic synapses is less well defined but seems to be more 
orchestrated, with several factors determining gephyrin clustering. The gephyrin 
recruiting molecules neuroligin 2 and collybistin possess consensus motifs for Pin-1 
binding. Gephyrin itself interacts with neuroligin 2 as well as with collybistin via its E-
domain. This interaction interface contains a Pin1 consensus sequence located 
within the neuroligin 2 binding site as well as directly adjacent to the collybistin 
binding domain (Harvey 2004). The consensus sequence contains a serine (S319) 
that has been reported to be phosphorylated in vivo (Tyagarajan et al. 2013). Pin1 is 
therefore competent to modulate the interaction of gephyrin with both of its major 
modulators. Moreover, the collybistin binding domain overlaps with the interaction 
site of GABAA-receptor subunits. Pin-1 dependent conformational changes at this site 
could therefore affect the recruitment of gephyrin by collybistin and neuroligin 2 as 
well as the subsequent immobilization of GABA receptors. This conformational switch 
has therefore the potential to tune GABA transmission subsequent to 
phosphorylation events exerted on gephyrin. 
 
1.4.2.4 Other post-translational modifications of gephyrin 
In a mass spectroscopic analysis of rat gephyrin, 9 acetylated sites were found. 
Unexpectedly most of the acetylated sites were not prototypical lysine residues but 
serines or threonines and even more unexpectedly three of these sites were either 
phosphorylated or acetylated (Tyagarajan et al. 2013). The functional relevance of 
these acetylations is yet to be determined. It was speculated that acetylations and 
phosphorylations at phospho-/acetyl-sites may happen contrary to each other in 
order to prevent the one or the other. For instance, S268 was found to be acetylated 
in this study which suggests that protein acetylation might add another regulatory 
step to prevent phosphorylation at this site by ERK1/2 and subsequent 
downregulation of GABAergic transmission. 
The dynamic regulation of the number of GABAA-receptors provides a key 
mechanism for functional plasticity of inhibitory synapses (Luscher et al. 2011). 
Reversible palmitoylation has emerged as the most frequent lipid modification of 
synaptic proteins with diverse effects on protein trafficking, neuronal development 




to identify neuronal palmitoylated proteins, gephyrin was identified as a candidate 
(Kang et al. 2008). It was confirmed later that gephyrin is palmitoylated at cysteine 
212 and 284 by palmitoyl acyltransferase DHHC-12 and that this modification 
represents an important mechanism to strengthen GABAergic transmission regulated 
by GABAA-receptor activity (Dejanovic et al. 2014). 
Gephyrin has also been reported to be a target of sumoylation. Sumoylation occurs 
at lysine-residues and is able to exert various effects including modifications of 
protein-protein interactions, scaffolding functions or neurotransmitter trafficking and 
function. Overexpression of sumoylating or de-sumoylating enzymes have shown to 
influence gephyrin cluster size (Tyagarajan et al. 2012). 
Neuronal activity-induced proteolytic cleavage by calpain negatively regulates 
gephyrin cluster size. Pre-requisite for this regulation seems to be phosphorylation at 
S268 or S270 by ERK or GSK-3β. Calpain could exert an additional effect on 
gephyrin clustering by producing single G and E domains that alter gephyrin 
clustering properties.  
 
1.5 Mechanistic target of rapamycin 
mTOR is an evolutionary conserved serine/threonine protein kinase that forms two 
functionally distinct signalling complexes that are regulated by numerous factors like 
amino acids -, glucose -, and ATP/ADP levels, growth factors, neurotransmitters or 
hormones (Figure 3). The two mTOR signalling complexes, mTOR complex 1 
(mTORC1) and mTOR complex 2 (mTORC2) regulate metabolic processes like cap-
dependent protein translation, energy metabolism, lipid synthesis, cell size, 
autophagy, mitochondria and lysosome biogenesis (Laplante and Sabatini 2012). In 
the nervous system, mTOR plays a key role in integrated physiological processes 
like neuronal development, brain plasticity, learning, memory storage, and cognition. 
Aberrant mTOR signalling contributes to many pathological conditions ranging from 
cancer to psychiatric disorders (Bockaert and Marin 2015). The medical application 
of mTORC1 inhibitors has shown to be beneficial in the treatment of tuberous 
sclerosis, epilepsy, and different forms of cancers, while activation of mTORC1 
signalling has been shown to ease the symptoms of clinical depression (Costa-




Rapamycin is a natural macrolide antibiotic produced by the bacterium Streptomyces 
hygroscopius that was first isolated in the 1970s from soil samples collected at the 
easter islands, also known as Rapa Nui. It was later described to have 
immunosuppressant effects and to reduce eukaryotic cell proliferation (Chang and 
Sehgal 1991). In a genetic study in yeast, it was shown that mutations in three genes 
Fpr1, Tor1 and Tor2 rendered cells insensitive to the toxic effects of rapamycin 
(Cafferkey et al. 1993; Helliwell et al. 1994; Chen et al. 1995). This was the 
foundation for the revelation of one of the most important signalling pathways in 
biology: the mTOR pathway. 
mTOR is expressed in every cell type and regulates a number of fundamental cellular 
processes. In the brain, mTOR also affects specific neuronal functions like axonal 
outgrowth (Abe et al. 2010), axon regeneration (Liu et al. 2010), myelination (Bercury et 
al. 2014; Wahl et al. 2014; Lebrun-Julien et al. 2014), neurotransmitter receptor 
expression (Duman et al. 2012) or dendritic spine growth (Tavazoie et al. 2005; Tang et 
al. 2014). Deregulation of mTOR signalling in the brain has been associated with 
psychiatric conditions like clinical depression or schizophrenia but also severe 
neurodevelopmental disorders like fragile X syndrome, Down syndrome, autism 
spectrum disorders, mental retardation, tuberous sclerosis, neurofibromatosis or Rett 
syndrome (RTT). 
Many of the syndromes listed above are caused by or involve upregulated mTORC1 
signalling. Some symptoms of these pathologies could be reversed by mTOR 
inhibition in the corresponding animal models, raising options for treatments in 
humans.  
 
1.5.1 Structure function regulation of the mTOR complexes 
The amino acid sequence of mTOR comprises of 2549 residues. A stretch of 20 
tandem HEAT repeats (short for Huntington, EF3, A subunit of PP2A, TOR1) is 
located at the N-terminus. In crystal structures this region is split up into two lobes 
that are known sites for protein-protein interactions. This segment is followed by a 
FAT (FRAP, ATM, TRAP) domain and the N- and the C-lobe of the kinase domain. 
The C-lobe contains the FRB site (for FRBP12-rapamycin-binding domain) while the 




a constitutive member of both mTOR complexes (Yang et al., 2013). Another FAT 
domain termed FATC is located at the very C-terminus and seems to be necessary 
for mTOR activity (Hay 2004). 
mTOR associates with different proteins to form two functionally distinct complexes: 
mTORC1 and mTORC2. Both complexes also share some of their components like 
the already mentioned mLST8. Another one is DEPTOR (DEP domain-containing 
mTOR-interacting protein) a protein that inhibits mTORC1 and mTORC2 upon 
overexpression. DEPTOR binds to the FATC domain of mTOR. Another common 
element of mTORC1 and 2 is the Tti1/Tel2 complex which binds to the second 
portion of HEAT repeats and is critical for TORC assembly (Laplante and Sabatini 
2012). 
mTORC1 specific subunits are Raptor (regulatory associated protein of mTOR) and 
PRAS40 (proline-rich Akt substrate of 40 kDa). Raptor is an activator of mTOR and 
binds to the N-terminal HEAT repeats and to the FATC domain while PRAS40 binds 
to and thereby inhibits Raptor. mTORC1 is sensitive to nutrients like amino acids and 
glucose, energy levels, some growth factors that regulate protein translation, energy 
metabolism, lipid synthesis, autophagy and lysosome biogenesis. 
mTORC2 specific subunits are Rictor (rapamycin-insensitive companion of mTOR), 
mSin1(mammalian stress-activated Map kinase-interacting protein1) and Protor 
(protein observed with Rictor 1/2). mSIN1 is a scaffolding protein for the downstream 
serum/glucocorticoid-regulated kinase 1 (SGK-1), Rictor is a scaffolding protein for 
the assembly of the whole complex and Protor1/2 facilitates the activation of SGK-1. 
mTORC2 is sensitive to growth factors which control survival, apoptosis, proliferation 
and cell shape. 
 
1.5.2 mTORC1 effectors 
Among the known targets of mTORC1 are translational regulators like 'eukaryotic 
translation initiation factor 4E-binding proteins' (4E-BP1/2/3) and the 'p70 ribosomal 
S6 kinase 1 and 2' (S6K1/2). The binding of 4E-BPs to 'eukaryotic translation 
initiation factor 4E' (eIF4E) inhibits cap-dependent translation of mRNAs. The 
activation of mTORC1 phosphorylates the 4E-BPs and releases the inhibition of 




to positively regulate translation, including the S6 subunit of ribosomes, eukaryotic 
elongation factor-2 kinase (eEF2K), eIF4B, S6K1 Aly/REF (SKAR)-like substrate and 
cap-binding protein 80 (CBP80) (Zoncu et al. 2011). 
Simultaneously activated S6K1 promotes the transcription of 5S ribosomal RNA and 
transfer RNAs and thereby contributes to ribosome biogenesis and protein translation 
(Iadevaia et al., 2014). mTORC1 contributes to protein translation in an indirect 
fashion by inducing the expression of proteasome genes. This leads to increased 
proteasomal degradation which increases amino acid concentrations in the cell 
(Laplante and Sabatini 2012; Zhang et al. 2014). 
Even though operating downstream of mTORC2, mTORC1 activity can alleviate 
mTORC2 by negative feedback regulation of S6K1 onto insulin receptor substrate 
(IRS). S6K1 phosphorylates IRS at S270 and S1101, priming it for sequestration, 
thus mediating insulin resistance (Ueno et al. 2005; Zhang et al. 2008). 
In contrast, a positive feedback mechanism was described by Julien and colleagues 
(2010), in which S6K1 phosphorylates Rictor at T1135 which increases Akt 
phosphorylation by mTORC2. 
mTORC1 is an effective activator of lipid metabolism. S6K1 mediated 
phosphorylation of transcription factor 'sterol regulatory element-binding protein-1/2' 
(SREBP1/2) induces the expression of several genes that are involved in fatty acid 
and cholesterol synthesis. Furthermore, adipogenesis-inducing 'peroxisome 
proliferator-activated receptor-γ' (PPAR-γ) is activated by SREBP1 (Peterson et al. 
2011). 
Catabolic processes like mitophagy or macroautophagy that are activated by 
starvation are negatively regulated by mTORC1 activity. mTORC1 directly inhibits the 
action of autophagy-inducing ULK1/Atg13/FIP200 complex (Dunlop and Tee 2014). 
In cancer cells, mTORC1 activity increases transcription and subsequent translation 
of hypoxia inducible factor 1α (HIF1α) that promotes glucose metabolism, cell 





1.5.3 mTORC2 effectors 
The central protein kinase Akt is downstream of mTORC2 activation. mTORC2 
phosphorylates Akt at S473 which renders Akt fully active (Sarbassov 2005). This 
phosphorylation event is required for some of the Akt substrates such as forkhead 
box O (FoxO) transcription factors. Akt phosphorylates FoxO proteins at residues 
critical for nuclear export which removes FoxO from the nucleus and annihilates its 
signalling (Guertin et al. 2006). In parallel, mTORC2-induced eradication of nuclear 
FoxO proteins can be mediated by serum- and glucocorticoid-induced protein kinase 
1 (Garcia-Martinez and Alessi, 2008; Pierce et al., 2011). Another target of Akt is the 
TCS1/2 complex. Akt phosphorylation of TSC2 inhibits its GTPase activity for 'Ras 
homolog enriched in the brain' (Rheb). Rheb itself activates mTORC1 by an unknown 
mechanism making mTORC2 ultimately an upstream activator of mTORC1 (Inoki et 
al. 2003). 
A major function of mTORC2 is the regulation of actin polymerization by activation of 
PKC and Rac1 (Guertin et al. 2006; Thomanetz et al. 2013). One of these 
mechanisms involves recruitment of the GEF P-Rex1 into mTORC2 and subsequent 
activation of Rac1 (Hernandez-Negrete et al. 2007). Rac1 is a member of the Rac 
subfamily of the Rho family of GTPases. Rac1 is a pleiotropic regulator of many 
cellular processes including actin polymerization, lamellipodia formation and cell 
migration. 
 
1.5.4 Activation of mTORC1 
Most of the activating cues for mTORC1 come from extracellular signals. They are 
transmitted through cytokine receptors, ion channels, G protein-coupled receptors 
and receptor tyrosine kinases, and converge onto the TSC1/TSC2 complex. This 
dimeric complex of TSC1 (hamartin) and TSC2 (tuberin) represents a GAP for the 
mTORC1-activating Rheb. So far there is no known GEF for Rheb that could 
recharge inactive Rheb-GDP with GTP (Long et al. 2005). The TSC1/2 complex is 
targeted by central kinases like Akt, IκB kinase β (IKKB), extracellular signal-
regulated kinase (ERK) and ribosomal S6 kinase (RSK) which all result in 
phosphorylation and subsequent inhibition of TSC1/TSC2 activity and thereby to a 




An important modulator of the PI3K/Akt/mTOR signalling axis is the lipid 
'phosphatase and tensin homolog' (PTEN). It counteracts the action of PI3K as it 
hydrolyses phosphatidylinositol-(3,4,5)-triphosphate at the plasma membrane to 
interrupt the activation of Akt. 
Another important activator of mTORC1 signalling is cyclic adenosine 
monophosphate (cAMP). cAMP levels regulate the formation of mTORC1, probably 
by a protein kinase A (PKA) mediated inactivation of PRAS40 or via the release of 
Rheb from sequestration by phosphodiesterase 4D (PDE4D) (Blancquaert et al. 
2010; Kim et al. 2010). 
Activation of mTORC1 by amino acids is facilitated by the activity of four different 
regulatory protein complexes and the recruitment of mTORC1 to the lysosomal 
compartment by Rheb. Rag family GTPases RagA or RagB form obligate 
heterodimers with RagC or RagD. Each Rag dimer-subunits binds either GTP or 
GDP depending on the amino acid concentration. Amino acid stimulation promotes 
the formation of RagA/BGTP-RagC/DGDP dimers which activate mTORC1 while amino 
acid deprivation promotes the formation of RagA/BGDP-RagC/DGTP dimers that inhibit 
mTORC1 formation. Prerequisite for this regulation is the recruitment of mTORC1 to 
LAMP1/2-positive lysosomal compartments via farnesylated Rheb. There mTORC1, 
interacts with the Rag heterodimers and the inhibitory Ragulator complex. Ragulator 
exhibits GEF activity and activates RagA/B at the lysosome. Inversely, a regulatory 
protein complex called GATOR1, possesses GAP activity towards RagA/B and 
inactivates Rag heterodimers. A third regulatory protein complex called GATOR2 
suppresses GATOR1. Inactivation of GATOR1 renders mTORC1 insensitive to 
amino acid deprivation while inactivation of GATOR2 can suppress mTORC1 














1.5.5 Inhibition of mTORC1 
Low energy levels are a major inhibitory factor for mTORC1 signalling. Cells limit 
energy-consuming processes like protein translation upon starvation. High 
concentrations of AMP activate '5'-AMP-activated protein kinase' (AMPK) which is a 
potent inhibitor of mTORC1 formation and functions as a major antagonist of Akt 
signalling. Activated AMPK phosphorylates TSC2 at S1345 and T1227 which 
enhances TSC1/2 inhibitory activity towards Rheb. In parallel AMPK phosphorylates 
Raptor at two inhibitory serine residues and renders it inactive (Gwinn et al., 2008). 
The action of AMPK therefore represents a metabolic checkpoint coordinating cell 
growth with energy status (Inoki et al. 2003). 
Hypoxic conditions lead to high AMP/ATP levels but AMPK activation seems to be 
independent of that. Instead, stabilisation of the transcription factor 'hypoxia induced 
factor 1' (HIF1α) leads to the transcription of HIF1α target-genes which activate 
TSC1/TSC2 complex (Inoki et al. 2005). Moreover high reactive oxygen species 
levels, observed under hypoxic conditions are able to inactivate mTORC1 at the 
peroxisome and the mitochondrial level (Li et al. 2010; Benjamin and Hall 2013). And 
finally DNA damage can initiate p53-dependent transcription of TSC2 and PTEN but 
in parallel also directly activated TSC1/TSC2 complex via GADD34, which 
counteracts the effect of IKKB, RSK and Akt-dependent inactivation of the TSC2.  
 
1.5.6 Activation and inhibition of mTORC2 
Little is known about the upstream activators of mTORC2. In Dictyostelium 
dicoideum, G-protein coupled receptors (GPCRs) mediate chemotactic signals which 
specifically regulate mTORC2 independently of PI3K (Lee et al. 2005; Kamimura et 
al. 2008). Moreover, the association with the TSC1/2 complex and ribosomes appear 
to regulate mTORC2 positively (Zinzalla et al. 2011). 
It has been described that mTORC2 is inhibited by mTORC1 overactivation due to a 





1.5.7 mTOR complexes in brain physiology 
The expression and subcellular localization of neuronal mTOR and its complexes has 
not been studied in detail yet. However, there are data from non-neuronal cells that 
suggests that active mTORC1 is targeted to cellular organells by its interaction 
partners Rheb, Gator complexes, Ragulator and vATPase. Rheb, the major activator 
of mTORC1, is farnesylated and therefore likely to be targeted to intracellular 
membranes such as mitochondria, peroxisomes, lysosomes, late endosomes or the 
Golgi apparatus. Moreover, Rheb directly interacts with plasma membrane receptors 
like the NMDA receptor. In order to understand the mTORC1 and mTORC2 
dependent signalling pathways better in context of neuronal cells, detailed knowledge 
about their subcellular localization and activity is necessary. 
Aberrant mTORC1 signalling has been implicated in multiple physiological and 
pathological states throughout the nervous system. Neurotoxins that induce the 
disruption of calcium homeostasis have shown to inactivate mTORC1. In contrast, 
the overactivation of Akt, Rheb or a disruption of PTEN and consequently an 
overactivation of mTORC1 has been observed in numerous brain pathologies like 
tuberous sclerosis, epilepsy, schizophrenia or autism spectrum diseases. The 
Induction of autophagy by suppression of mTORC1 signalling has been shown to be 
beneficial in treatment of these pathological processes. 
Neurons of the peripheral nerve system are able to regenerate after injury by axonal 
sprouting and healing due to increased mTORC1 signalling. In contrast, in several 
models of central nervous system neuron injury a downregulation of mTORC1 
signalling has been observed, which results in the inability of regeneration and 
healing. Axon sprouting and healing can be induced in these models by activation of 
mTORC1. 
 
1.5.7.1 Dysregulation of mTOR in neurodevelopmental disease 
Neurodevelopmental disorders are impairments of the growth and development of 
the central nervous system. A more narrow definition considers disorders that affect 
brain functions like emotions, learning ability, self-control and memory that are 
manifested during growth of an individual. Autism spectrum disorders (ASDs) 




present common symptoms like impaired social interactions, abnormal repetitive 
behaviours and intellectual disability. Usually there is a genetic background with 
some forms of ASDs being linked to single genes. ASDs are heritable but they also 
occur spontaneously within the germline.  
Some ASDs could be connected to mutations in negative regulators of mTORC1 
signalling like TSC1, TSC2 or PTEN and mouse models of these diseases exist that 
partially reproduce the disease phenotype. These models were used to assess the 
potential of pharmacological modulation of mTORC1 signalling in respect to 
improvement of autistic behaviours, epilepsy, memory or learning. 
Rapamycin has shown to reverse some of the behavioural and anatomical 
abnormalities in mouse models of neurodevelopemental disorders. Prolonged 
treatment with rapamycin in adult TSC2 +/- mice for instance improves the deficient 
cognitive and plasticity phenotypes (Chen et al. 1995; Cota et al. 2008). 
The conditional inactivation of TSC1 in astrocytes, neurons or microglia leads to 
astrogliosis, macroencephaly, seizures and premature death (Crino et al. 2006; 
Cunningham et al. 2007; Crews et al. 2010; Aryal et al. 2014). Mice with conditional 
inactivation of TSC2 in radial glia develop astrogliosis, lamination defects, enlarged 
dysmorphic neurons and premature death. The chronic treatment with rapamycin has 
shown to be beneficial as it decreases the frequency of seizures and improves the 
lifespan of these mice. 
ASD patients carrying mutations in their TSC1 or TSC2 gene show a loss of 
cerebellar Purkinje cells. Deletion of TSC1 in Purkinje cells effects social interaction 
and causes repetitive behaviour in mice, which recapitulated some of the behavioural 
deficits in humans. These mice also proof that behaviour is in part modulated by the 
cerebellum. 
Conditional inactivation of PTEN in the brain leads to hypertrophic neuronal 
phenotypes, macroencephaly and seizures (Durán and Hall 2012; Dunlop and Tee 
2014). Neuron-specific PTEN inactivation leads to abnormal social behaviour, 
impaired spatial learning, seizures and morphological changes that can in part be 
rescued by administration of rapamycin. Functionally PTEN inactivation has 




(LTD). Also postnatal deletion of PTEN has shown to block synaptic plasticity but has 
no impact on the neuronal or synaptic structures per se. 
Synaptic plasticity leads to either a long-term increase or a long-term decrease in 
synaptic transmission and are results of neuronal activity. It can be ectopically 
induced by electrical or pharmacological stimulation. LTD and LTP are believed to be 
cellular correlates of memory formation. LTP is classically divided into two stages, an 
early and a late stage. The early stage is characterized by rapid changes of 
posttranslational modifications like phosphorylation of the pre-existing synaptic 
components. The later stage shows changes in the synaptic content and requires 
protein translation, degradation and cytoskeletal rearrangements. In CA1 neurons 
late LTP is triggered by NMDAR activity and subsequent activation of mTORC1 and 
its effector kinase S6K. This activation seems to be spatially organized since it 
happens mostly in dendrites and to a less extend in spines but not in the cell body. 
The late stage induction of translation depends on the early stage activation of 
mTORC1 since it can be inhibited by administration of rapamycin. 
The activation of mTORC1 by NMDAR activity is thought to be mediated by calcium 
influx through voltage dependent calcium channels and thus local increase of cAMP 
concentration. But also an indirect effect of autocrine BDNF signalling via the Trk-β 
and the canonical PI3K-Akt-mTOR pathway is possible. 
 
1.5.7.2 Epilepsy 
Epilepsy is chronic neurologic disorder and one of the most frequent symptoms in 
neurodevelopmental disorders. Epileptic seizures, in absence of other associated 
pathologies increase mTORC1 signalling, a positive feedback mechanism that could 
contribute to progressive epileptogenesis. A classical morphological feature in 
patients with temporal lobe epilepsy is axonal sprouting of dentate granule cells. 
Rapamycin administration beginning directly after a seizure reduces axonal spouting, 
seizure frequency and neuronal cell death but has no effect on neurogenesis (Zeng 
et al. 2009; Buckmaster et al. 2009; Huang et al. 2010).  
The WAG/Rij rat is a model of absence epilepsy. mTORC1 signalling is upregulated 
in the hippocampus of these rats and rapamycin administration before onset of 




that mTORC1 overactivation might be a trigger of epileptogenesis (Russo et al. 
2014). 
The neuron specific as well as the astrocyte specific conditional TSC1 and TSC2 
inactivation model that recapitulates symptoms of TSC patients, frequent 
spontaneous seizures can be reduced by rapamycin. In the animal model as well as 
in the patient reoccurring seizures are the most disabling neurological symptom. The 
cause for seizures is decreased activity of GABAergic neurons which results in 
network hyperexcitability. The connection between reduced GABA activity and 
mTORC1 signalling is not yet known. 
 
1.5.7.3 Depression 
Alteration in mTORC1 signalling have been implicated in clinical depression one of 
the most frequent psychiatric disorders. This implication represents a new angle in 
mTORC1 signalling since mTORC1 seems to be downregulated in depression. 
Chronic stress as well as by long-term corticosterone treatment can inhibit the PI3K-
Akt-mTOR signalling pathway (Howell et al. 2011). Also cyclosporin A or tacrolismus 
chronically injected into the prefrontal cortex of rats induces depressive-like 
behaviours that can be reversed by NMDA-mediated activation of mTORC1 (Yu et al. 
2013). Ketamine, a potent NMDA receptor antagonist is known to elicit rapid and 
long-lasting antidepressant effect. mTORC1 has been identified as a specific 
downstream effector of ketamine. Ketamine inhibits NMDA receptors preferentially on 
GABAergic interneurons, which leads to a disinhibition of glutamatergic neurons, 
increased depolarization and BDNF release. BDNF activates mTORC1 by binding to 
Trk-β receptor and thereby starting the PI3K-Akt-mTOR signalling pathway which 
increases the translation of synaptic proteins like PSD95 and glutamate receptors. 
 
1.5.7.4 Rett syndrome 
Rett syndrome is a neurodevelopmental disorder that almost exclusively affects girls 
with a prevalence of 1 in 10000 births (Hagberg et al. 1983). It was first described by 
Andreas Rett, an Austrian paediatrician in 1966. Even though age of onset and 




that a period of apparently normal development is followed by a developmental 
stagnation which pursues into a phase of regression. Early symptoms are an arrest 
of head growth which usually leads to microencephaly, reduction or loss of acquired 
skills such as purposeful use of the hands, vocalization and communication skills. 
Another characteristic of the disease are the intense and continuous stereotypical 
hand movements that appear after loss of purposeful hand movements. Moreover 
breathing irregularities, autism-like behavior, seizures, growth retardation and cardiac 
abnormalities are key features of the disease (Shahbazian and Zoghbi 2001). 
Rett syndrome can be divided into 4 stages. The onset of the first stage is between 6 
and 18th month of age and is characterized by a developmental stagnation that may 
not be noticed immediately. The second stage usually begins between 1 and 3 years 
and shows a rapid developmental degression. The infant loses purposeful hand 
movements and language. Stereotypical hand movements such as wringing, washing 
and mouthing may start during this phase. Other symptoms appearing in this state 
are breathing irregularities characterized by episodes of hyperventilation and apnoea, 
social withdrawal, loss of communication and decreased motoric abilities. The 
following third stage is characterized by a pseudo-stationary state. Prominent 
features are generalized apraxia and reoccurring seizures. This stage can last for 
years and may show improvement in the autistic behavioural features. The fourth 
stage, or motor deterioration-phase, can last for years or even decades. It is 
characterized by muscle weakness, rigidity, spasticity, dystonia and scoliosis and 
hence loss of mobility. Stereotypic hand movements usually become simpler in this 
stage and general eye contact and communication remain intact (Weaving et al. 
2005). 
 
1.5.8 Genetic background of Rett syndrome 
Rett syndrome is caused by mutations in the methyl CpG binding protein 2 (MeCP2) 
encoding gene located at the X-chromosome. In 80-90% of all cases these are de-
novo mutations (Shahbazian and Zoghbi 2001). MeCP2 is a transcriptional regulator 
that binds to 5-methylcytosine, methylated cytosines within cytosin-phosphate-




mutations in MECP2 are C to T mutations within one of the eight CpG dinucleotides 
(Lee et al., 2001). 
Due to random X-inactivation girls with RTT represent a mosaic of healthy and 
diseased cells on tissue level. However skewed X-activation leading to non-random 
inactivation, favouring one of the X-chromosomes may explain the high variability in 
RTT phenotype manifestation (Plenge et al. 2002; Weaving et al. 2005). 
 
1.5.9 MeCP2 protein function 
MeCP2 is a transcriptional regulator that binds to methylated cytosines in CpG 
dinucleotides. CpG dinucleotides are often found in the promoter region of genes and 
in heterochromatin. The methylation of CpGs inside promoter regions usually leads 
to silencing of that particular gene. In contrast, hypomethylation of CpGs has been 
associated with protein overexpression (Meehan et al. 1989). 
The human MECP2 gene comprises if 4 exons and gives rise to 2 isoforms by 
alternative splicing. The two isoforms are very similar as they share all the functional 
domains but they vary at the start. The m-RNA of isoform MeCP2e1 comprises of 
exon 1, 3 and 4 while mRNA of isoform MeCP2e2 comprises of exon 2, 3 and 4. 
Isoform 1 is considered to be the predominant isoform expressed in the brain 
(Dragich et al. 2007). The protein harbours three functional domains: a methyl-CpG-
binding domain (MDB), a transcriptional repressor domain and a nuclear localization 
sequence (Lewis et al. 1992). MeCP2 can repress transcription by binding to 
methylated CpG dinucleotides and subsequent recruitment of co-repressor Sin3A 
and histone deacetylase (HDAC) and BRM ATPase (Vecsler et al. 2010). This 
complex promotes the deacetylation of histones and leads to silencing of the 
concerned promoter. Phosphorylated MeCP2 that binds to CDK5 cannot bind to 
methylated CpG dinucleotides and therefore fails to exert silencing effect on that 
particular gene. 
Furthermore MeCP2 associates with the transcriptional activator CREB1 at 
promoters of activated but not repressed targets in the hypothalamus. The 
expression of the vast majority of genes in the hypothalamus seems to be regulated 
positively by MeCP2, which lead to a revision of MeCP2's role as transcriptional 




The brain is the most affected by MeCP2 dysfunction. It is also the place where its 
expression is highest. Moreover the fact that the MeCP2 expression closely co-
incides the postnatal maturation of the brain is the reason for people to believe that 
MeCP2 is involved in neuronal and synaptic maturation and maintenance. Several 
neuronal genes have been observed to be dysregulated upon MeCP2 inactivation in 
mice (Pelka et al. 2006; Smrt et al. 2007). One of the most prominent ones is Bdnf, 
encoding brain derived neurotrophic factor (BDNF). BDNF is a neurotrophin and 
potent modulator of neuronal development, synaptic transmission and plasticity. A 
loss of BDNF function leads to severe neurodevelopmental, neurodegenerative and 
neuropsychiatric diseases (Zuccato and Cattaneo 2009; Autry and Monteggia 2012). 
In rodents BDNF expression closely coincides MeCP2 expression. Conditional 
deletion of BDNF in forebrain excitatory neurons results in phenotypes similar to 
those in MeCP2 null mice, such as hind limp clasping, decreased brain weight, 
smaller olfactory and hippocampal neurons (Guy et al. 2001; Chang et al. 2006). The 
finding of BDNF expression being controlled by MeCP2 would also explain the 
general brain atrophy, reduction in dendritic arborisation as well as reduced number 
of synapses observed in the MeCP2 null mice. 
There are two models that aim to explain how MeCP2 controls transcription of Bdnf 
One of them being the repression model, based on the finding that MeCP2 binds to 
Bdnf promotor IV in cultured hippocampal neurons and prevents transcription. Upon 
depolarisation, MeCP2 is phosphorylated and subsequently released from the 
promoter site to allow transcription of Bdnf. Neuronal activity causes fast 
phosphorylation of cAMP response element binding protein (CREB1) which is a 
requirement of BDNF expression. Other mechanisms that underly the enhancement 
of Bdnf transcription upon MeCP2 unbinding are DNA demethylation and unbinding 
of co-repressors. The repression model fails to explain the fact that BDNF protein 
expression is lower in MeCP2 knockout mice. In the hypothalamus BDNF levels 
correlate with the expression of MeCP2, being lower in the MeCP2-KO and higher in 
the MeCP2 overexpressing mice when compared to wildtype (WT) controls 
(Chahrour et al., 2008). 
Long-term potentiation is a form of synaptic plasticity that relies on long-term 
changes in synapse anatomy and relies on de-novo synthesis of synaptic proteins. It 




maintenance has been correlated with general learning and memory deficits. 
Electrophysiological studies in hippocampal slices of MeCP2-KO mice revealed 
impairments in LTP compared to WT mice (Asaka et al. 2006). 
Several studies have demonstrated that BDNF participates in synaptic plasticity and 
is critical for dendritic spine formation and maturation during development (Poo 2001; 
Tyler 2002; Tanaka et al. 2008; Cohen et al. 2011). Exogenously applied BDNF 
increases spine density in cultured hippocampal neurons and CA1 pyramidal 
neurons in slice cultures (Tyler and Pozzo-Miller 2001; Ji et al. 2005). BDNF 
application also shifts the proportion of morphological types of spines. 
Overexpression of BDNF can rescue the dendritic atrophy caused by transient 
knockdown of MeCP2 in cultured hippocampal neurons. At dendrites BDNF binds to 
tropomyosin related kinase B (TrkB) receptor and activates ERK, PI3K and PLC-γ. 
Dendritic spine anomalies have been identified in multiple brain regions in RTT and 
MeCP2 inactivation models. Since BDNF promotes the formation, maintenance and 
activity-dependent remodelling of dendritic spines, its reduced expression upon 




First described by Theodore Förster over 60 years ago, Förster resonance energy 
transfer (FRET) is a dipole-dipole interaction that occurs between two fluorophores 
that possess a spectral overlap between the donor's emission and acceptor's 
absorbance (Figure 4a). It is important to note that the transfer of energy is non-
radiative, i.e. it does not involve emission and re-absorption of photons (Förster 




where τD is the excited state lifetime of the donor and R is the distance separating 
the fluorophores. As the FRET critical distance (R0 – Förster distance) between two 
fluorophores correlates inversely to the 6th power of separation distance, the FRET 




(Figure 4b) (Berney and Danuser 2003; Lakowicz 2006). The R0 distance is defined 
by the spectral properties of the FRET pair, and represents the distance at which E is 
50% (Lakowicz 2006): 
8.79 ∗ 10  
where κ2 is the orientation factor between the two fluorophores, QD is the donor 
quantum yield and J(λ) represents the overlap of donor emission and acceptor 
absorbance spectra. The overlap integral, J(λ) is defined as (Lakowicz 2006): 
 
where FD(λ) is the normalised fluorescence emission and εA(λ) is the molar extinction 
coefficient of the acceptor absorbance spectrum (Lakowicz 2006). 
Distances between 1 – 10 nm can be measured using FRET, making its application 
in cellular imaging ideal for the visualisation of interactions on the nm length scale 
(Wu and Brand 1994; Clegg 1995; Patterson et al. 2000; Akrap et al. 2010). The 
continued development of fluorophores has enabled FRET applications in life 
sciences, where elucidation of signalling pathways and/or partners is often 
dependent on the ability to resolve transient interactions of multiple biomolecules. 
In order to ‘pair’ fluorophores for use in measuring FRET, they must fulfil a number of 
criteria. Firstly, for optimal FRET, the spectral overlap between donor fluorescence 
and acceptor absorbance must be as large/extensive as possible. Additionally, the 
donor quantum yield and acceptor extinction coefficient must be as high as possible. 
Intensity-based FRET furthermore requires a bright acceptor so that the FRET-
induced ‘sensitised’ emission can be easily detected. Lastly, the angular orientation 
of dipole transition moments of the donor and acceptor fluorophores is an important 
factor in the efficiency of FRET. This is described by the orientation factor κ2 in the 
description of R0, and it's values can range between 0 and 4. A value of 0 
corresponds to a perpendicular orientation of donor and acceptor dipole moments, 
which is not capable of FRET, and 4 corresponds to a collinear orientation which 
results in maximal FRET efficiency. In a completely averaging regime, where 
fluorophores are assumed to possess complete rotational freedom, the statistical 
average over all sampled orientations amounts to a value for κ2of 2/3. This value is 
typically used for the calculation of R0 values in lists of FRET pairs. However, if the 




invalidate the assumption of a κ2of 2/3. Thus, the value for R0 might significantly 
deviate from the expected values that are based on the averaging regime. This is 
also the reason why great care should be taken in the estimation of separation 
distances from FRET efficiencies. 
In measuring FRET, these requirements are not always able to be optimised. 
Maximising spectral overlap introduces bleed-through of donor emission to the 
acceptor channel and the excitation of the acceptor at donor wavelengths, problems 
that require extensive correction in sensitised emission FRET (Berney and Danuser 
2003). As a large section of the available spectral window is occupied when the 
emission of two fluorophores is monitored, the use of multiple FRET pairs often 
difficult (He et al. 2005; Ai et al. 2008) (Figure 4). 
 
1.7 FLIM 
FRET between donor and acceptor fluorophores quench the donor fluorescence in 
proportion to the efficiency of FRET as the fluorescence lifetime is proportional to the 
fluorophores’ ‘specific brightness’, i.e. its quantum yield. This change in lifetime can 
be observed by fluorescence lifetime imaging microscopy (FLIM) (Bastiaens and 
Squire 1999; Lakowicz 2006).  
As the fluorescence lifetime is an intrinsic property of a particular fluorophore and 
independent of fluorophore concentration, FLIM is advantageously compared to 
intensity-based FRET measurements. In contrast to intensity-based FRET 
measurements, donor lifetime measurements suffice to detect environmental 
changes, and the measurement puts no demands on the acceptor quantum yield 
characteristics (Bastiaens and Squire 1999; Chen et al. 2003). It is even possible, 
and in some cases beneficial, to utilise non-fluorescent acceptors to measure FRET-
FLIM (Ganesan et al. 2006). The use of ‘dark’ acceptors in FLIM measurements 
allows wider detection range for donor emission. More advanced FRET–FLIM 
measurements that involve the switching of the absorption properties of the acceptor, 
such as pcFRET, can be used (Subach et al. 2010; Petchprayoon and Marriott 2010; 
Don Paul et al. 2013). 
FLIM is generally subdivided into time domain (TD) or frequency domain (FD) 




the effects succeeding an excited fluorophore, but the acquisition and analysis of the 
data differ. In TD FLIM, fluorophores are excited by a train of very short discrete light 
pulses. The decay kinetics of the excited state are sampled by measuring the arrival 
time of the first photon with respect to the excitation pulse. FD FLIM, on the other 
hand, typically uses a periodically modulated light source, rather than light pulses, to 
determine the modulation in the emission signal that is generated by the duration of 
the excited state. This distortion causes changes in the time-integrated signal on a 
regular charge-coupled device (CCD) camera, from which the fluorescence lifetime 
can then be estimated. Both modes can be used in wide-field and scanning 
microscopes. Most common set-ups for FD FLIM utilise wide-field microscopy whilst 
TD FLIM is mostly based on laser scanning microscopy. The difference in 
methodology can be reflected in their biological applications with FD FLIM being 
faster and therefore applied to living cells, whilst TD FLIM requires longer acquisition 













1.7.1 Time domain FLIM techniques 
In TD FLIM, very short pulses (fs – ps) of light are used to sample the fluorescence 
decay of a fluorophore. Following data acquisition, the shape of the decay function is 
fitted to an exponential decay model to determine its fluorescence lifetime. The most 
common implementation is time-correlated single photon counting (TCSPC) where 
the arrival time of many single emitted photons are recorded with respect to the 
excitation laser pulse for the different scanned positions in the image. 
Current detectors exhibit ‘dead times’, i.e. a delay time in which the detector cannot 
record a new photon, that are long with respect to the lifetime, typically in the μs 
range. As most fluorophores have fluorescence lifetimes of a few ns, a large number 
of photons are missed by the detector while it resets. Recording a time-resolved 
decay curve from a single excitation burst of a fluorophore would require extremely 
fast detectors with a time resolution in the tens of picoseconds. As no such detector 
currently exists, TCSPC FLIM uses a periodic excitation scheme extended over 
multiple excitation events. In this way, a decay curve is reconstructed from single 
photon events collected over many cycles (Figure 5). In order to unambiguously 
assign the emission photon to the excitation event, the emission probability per event 
is kept low. As not every excitation pulse generates a photon, the excitation pulse 
immediately following a detected photon incident is used as a time reference in a 
‘reverse start-stop’ procedure. 
One major disadvantage of TCSPC FLIM is the long acquisition time. It can take up 
to 10 minutes or longer to gather enough photons for a reliable lifetime fitting 
procedure. In most cases the count rates of TCSPC FLIM systems are not the 
limiting factor. Count rates of TCSPC FLIM systems can range up to ten megacounts 
per second and is limited mainly by the photostability of the dye and the scanning 
speed of the microscope but not by the counting ability of the detection system 
(Katsoulidou et al. 2007; Becker et al. 2009). The optimisation for brightness of 
fluorophores like mCerulean3 (Markwardt et al. 2011) or mTurquoise2 (Goedhart et 
al. 2012) is one way to reduce the acquisition times. Additionally, the use of less 
photon-demanding fitting routines, e.g. Bayesian fitting (Rowley et al. 2011), can be 










While TCSPC FLIM aims to reconstruct the fluorescent decay profile by timing single 
photon events, an alternative method of sampling decay kinetics after a brief light 
pulse is to record photons in consecutive time bins. At the core of a time-gated FLIM 
system is the image intensifier. On arrival of photons at the photocathode, 
photoelectrons are produced by the photoelectric effect, which are then multiplied 
thousand-fold in the multichannel plate before generating photons on the anode 
phosphor screen that are imaged by a CCD camera. The image intensifier can be 
gated in time with high temporal resolution by application of a gating pulse (Dymoke-
Bradshaw 1993). As the intensifier gating is synchronised with the pulsed excitation 
signal, the camera is opened in the same relative period in successive excitation 
cycles, gaining time-integrated signals of the decay at arbitrary total exposure times. 
The decay is sampled at two or more positions in time. In case of two time gates of 
equal width and a mono-exponential fluorescence decay, the fluorescence lifetime 
can be easily determined from the ratio of the recorded intensities by the rapid 
lifetime determination (RLD) formula (Ballew and Demas 1991): 
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where I0 and I1 represent the images recorded in the first and second time bin and ∆τ 
is the gating time. For multi-exponential decay kinetics, the time-gating 
implementation with two time gates yields an average lifetime, which is sufficient to 
provide lifetime contrast of biological probes. More than two time gates have been 
shown to provide quantitative results for biological samples containing multi-
exponential decays (Scully et al. 1997; Esposito and Wouters 2004). 
Time-gated image intensifiers can be used with scanning microscopes (Wang et al. 
1991; Cole et al. 2001) but more interesting is the combination with wide-field set-ups 
because the CCD chip based detection system allows the simultaneous acquisition 
of all spatial information at once, translating in an increase in acquisition speed 
compared to sampling the image by scanning (Wang et al. 1992; Scully et al. 1996; 
Dowling et al. 1997). A faster way to record time-gated FLIM on a scanned system is 
via multi-beam scanning as described by (Straub and Hell 1998). 
The image analysis of the RLD method affords significantly shorter calculation time 
and is surprisingly robust and effective at providing lifetime-based contrasts in 




acquisition times are generally shorter than techniques based on spatial scanning. As 
the number of time gates is inversely proportional to photon counting efficiency, the 
more time gates used to sample the decay function, the fewer photons will be 
recorded. 
The problem of photon efficiency can be eased by recording in only a few time gates 
in combination with a single-shot detection configuration. Single-shot detection splits 
an image into two or more images using a beam splitter and each image is 
designated to a different time bin. In one implementation, one of the two images was 
projected immediately onto the gated image intensifier while the other image was 
delayed by taking a detour of several meters before being projected onto the same 
detector (Agronskaia et al. 2003). For simultaneous, parallel detection, the system is 
equipped with a four-channel optical splitter working in conjunction with a segmented 
gated image intensifier. Unlike a conventional image intensifier, the photocathode is 
subdivided into four quadrants by resistive sectioning, providing four channels, which 
can be gated at different delay times. The image splitter can therefore relay four sub-
images of the sample onto four quadrants of the detector (Elson et al. 2004). 
Despite the obvious speed advantage of gated wide-field FLIM setups, it should be 
noted that the lack of confocal out-of-focus light rejection can cause the mixing of 
fluorescent signals with different lifetime characteristics, thereby reducing lifetime 
contrast. 
 
1.7.2 TD FLIM image analysis 
Despite the relative simplicity and speed of the RLD method (Ballew and Demas 
1989), it only estimates the average lifetime of all lifetime components weighted by 
their individual contribution to the mixture. Most FLIM applications in life sciences 
must deal with multi-exponential decays, derived from mixtures of fluorophores, 
spectrally similar but possessing different lifetimes. The average fluorescence lifetime 
can be useful in the case of FRET as it provides contrast between the quenched and 
unquenched donor. However, due to the fact that the decay curve is strongly under 
sampled, it is not possible to extract single lifetimes from multi-exponential decay 
curves. Consequently, determining fractions of donor molecules, which do or do not 




The only technique providing direct access to parameters of multi-exponential decays 
is TCSPC FLIM. The data from TCSPC measurements usually consists of a large 
number of photons recorded in a many time channels for each pixel of an image. 
These photon numbers and corresponding time channels resemble fluorescence 
decay curves in each pixel of the image. Importantly, at this stage, the data is still a 
convolution of fluorophore data and the instrument response function (IRF). The IRF 
is the response of the detection system to only the excitation pulse and can be 
measured or calculated from the decay function by Fourier analysis. The 
deconvolved decay curve can then be fitted to a mathematical model of choice until 
the best fit is achieved (O’Connor 1984). 
 
1.7.3 Frequency Domain FLIM techniques 
FD FLIM employs an excitation light source which is periodically modulated in 
intensity rather than a train of very short excitation light pulses. The emitted 
fluorescence is shifted in phase and the amplitude is demodulated relative to the 
excitation light. The distortion in the temporal emission profile resulting from the time 
that a fluorophore spends in an excited state before emitting a photon is used to 
estimate the fluorescence lifetime (Figure 5). The modulation of the excitation can be 
a sinusoidal or block wave. Sine wave excitation will result in an emission sine wave 
of the same frequency, but shifted in phase (Φ) and with reduced amplitude. A block 
wave signal will lose higher-order frequencies as the emission will ‘smear out’ the 
sharp edges of the block wave. Provided that a lifetime is long enough, the block 
wave will result in a sine wave at the fundamental modulation frequency. These 





where τΦ is the phase lifetime, Φ the phase shift at every modulation frequency ω, τM 
is the modulation lifetime and M is the modulation.  




of the fluorophore. An analogue from elementary school physics helps us to 
intuitively understand the connection between lifetime, phase delay and the reduction 
in amplitude. Imagine a movable arm (modulated excitation) connected to a spring 
and a weight. Oscillation of the arm moves the weight and compared to the 
movement of the arm, movement of the weight is delayed in time and its amplitude is 
reduced. The parameter that defines delay and demodulation is the spring constant. 
In our model, it is equivalent to the fluorescence lifetime. A small spring 
constant/lifetime will result in a small phase delay while a large spring 
constant/lifetime will cause a large phase delay. The amplitude will be larger for small 
lifetimes and smaller for large lifetimes.  
As biological fluorophores usually possess fluorescence lifetimes in the nanosecond 
range, the excitation intensity is modulated at tens of Megahertz. If the modulation 
frequency is too low, the fluorescence will decay before the excitation cycle is 
completed. If the excitation frequency is too high, excited fluorophores will still be 
emitting whilst the excitation cycle starts again leading to saturation and an 
averaging-out of the modulation. Different lifetime components in a sample therefore 
require multiple frequencies (Colyer et al. 2008). The lifetime of a fluorophore can be 
determined directly via its phase delay or modulation ratio at different modulation 
frequencies. For single exponential decays, if the decay kinetics are best fit to a 
single exponential decay function, the lifetime phase shift and modulation change will 
be the same at all frequencies. If the decay is multi-exponential, then the lifetime 
phase shift will be smaller than the lifetime modulation change and their values will 
depend on the modulation frequency. Therefore, FD FLIM provides immediate 
information on lifetime heterogeneity. 
The high acquisition speeds of frequency domain FLIM make it an ideal technique for 
fluorescence lifetime measurements of living cells. One of the reasons why, time 
domain equipment is more widely implemented in laboratories and imaging facilities, 
is the relative complexity of frequency domain equipment. Particularly, the image 
intensifier is an expensive and vulnerable component that, additionally, degrades the 
image quality. 
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2 Aims of the thesis 
The intention of this thesis was to investigate the role of mTOR signalling in synapse 
formation and plasticity and its failure in Rett syndrome. mTOR signalling is 
compromised in mouse models of Rett syndrome. Therefore mTOR signalling was 
supposed to be analysed on single cell level in order to clarify the contribution of 
neuronal subpopulations in the expression of Rett syndrome. 
Firstly, optical sensors were developed, optimised, and evaluated to address the 
activity state of endogenous mTORC1/2. These sensors were designed with the 
foresight to be used in combination with the detection neuronal identity markers, 
allowing cell-type specific analysis of mTORC1 and 2 activities. 
Secondly, the role of mTOR in inhibitory synapse plasticity was to be elucidated. To 
this end, the interaction of mTOR with gephyrin, the major organiser of the inhibitory 
postsynapse, was studied and the aspects of this interaction were analysed.  
And lastly, the clustering of gephyrin and its regulation was quantitatively analysed by 
creating FRET sensors that report on the interactions of the G-domain and E-domain 
of gephyrin. These sensors were combined with the expression of the major 
regulators of gephyrin clustering to quantify their influence on the clustering process. 
The role of mTOR signalling in gephyrin clustering was addressed by pharmacologic 
inhibition of mTORC1 and mTORC2. 
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3 Materials and Methods 
3.1 Mice 
Animal care was conducted in the central animal facility of the University of 
Göttingen, according to institutional guidelines with a 12 h light/ 12 h dark cycle and 
ad libitum access to food and water. Genotypes of MeCP2 (B6129P2(C)-Mecp2tm-1-
1Bird, hereafter referred to as MeCP2-/Y) were determined prior to start of the 
experiment via polymerase chain reaction (PCR) from isolated tail tissue. Only male 
mice were used for experiments as the MeCP2 gene is located to the X-
chromosome.  
MeCP2 tmI.IBird KO mice of 0-1 day postnatally were obtained and sacrificed by 
decapitation. WT littermate controls were used for all experiments. Hippocampus was 
used to prepare a dissociated cell culture.  
 
3.1.1 The MeCP2 tmI.IBird KO mouse as a model of Rett syndrome 
Mice, lacking the MeCP2 gene (B6129P2(C)-Mecp2tm-1-1Bird), were used as a model 
organism for Rett syndrome. They were bred with C57BL/6J WT males to generate 
heterozygous females, hemizygous males and WT mice of either gender. 
 
3.1.1.1 DNA isolation and genotyping of MeCP2 tmI.IBird KO mouse 
DNA isolation 
Tail biopsies of P0-P1 mice were digested in 350 µl tail lysis buffer (50 mM Tris/HCl 
pH 8.0, 100 mM NaCl, 10 % SDS, 1 mM EDTA pH 8.0, 200 µg Proteinase K) for 
minimum 3 hours at 65° C, shaking. Debris was pelleted for 10 min at 20,000 g. 300 
µl supernatant was precipitated by adding 350 µl isopropanol and pelleted at 20,000 
g for 10 min. The pellet was washed with 70 % ethanol and dried for 30 min at 37° C. 
The DNA pellet was solved in 150 µl 10 mM Tris/HCl (pH 7.5). 
 
Genotyping PCR according to Miralvès et al., 2007 
The PCR reactions were performed in a final volume of 20 µl containing 20 ng tail 
DNA. The PCR cocktail was made up of 1×NEB PCR Reaction Buffer (New England 
Biolabs Inc., USA), 2,5 mM MgCl2, 200 µM dNTPs, 1 µM primers (Sigma-Aldrich, 
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USA) and 1 U Taq DNA polymerase (New England Biolabs Inc., USA). Primers used 
are shown below (Table 1) (Miralvès et al. 2007). 
PCR conditions were as follows: denaturation at 95° C for 30 seconds, annealing at 
64° C for 30 seconds and extension at 72° C for 40 seconds, followed by a final 
extension at 72° C for 7 minutes. The reactions were held at 4° C until analysis. 
PCR products were all analysed by 1.5 % agarose gel electrophoresis in 1× TAE 
buffer, stained with ethidium bromide (Roth, Germany) and photographed with a 
Peqlab transilluminator (Peqlab, Göttingen, Germany). The molecular weight marker 
used was 1000 bp DNA ladder (New England Biolabs Inc., USA). 
 
Table 1: Genotyping primers 
Primer name Primer sequence (5’ – 3’) 
P3 WT FW GACCCCTTGGGACTGAAGTT 
P3 KO FW CCATGCGATAAGCTTGATGA 
P3 RV CCACCCTCCAGTTTGGTTTA 
 
 
3.1.2 Primary neuronal cell culture 
Treatment of coverslips 
For neuronal cell culture coverslips were incubated for minimum 2 hours in 1 M HCl 
(Roth, Germany) at 60° C, before they were washed in acetone (Roth, Germany), 
70 % ethanol (Roth, Germany) and 99.9 % ethanol (Roth, Germany) for 1 hour each. 
Coverslips were dried of the ethanol and autoclaved. Before use single coverslips 
were coated with 0.01 % poly-L-lysine (Sigma-Aldrich, USA) or 0.04 % 
poly(ethyleneimine) (Sigma-Aldrich, USA) solution for 12 hours. Coverslips were 
rinsed three times with water before plating the cells. 
 
Primary cell culture  
Primary cultures of hippocampal neurons were prepared according to the method of 
Dotti et al., (Dotti et al. 1988) with slight modifications. Hippocampi from E18 rat 
brains or P0 mouse brains were washed with and collected in ice-cold calcium- and 
magnesium-free Hanks’ balanced salts solution (HBSS). Cells were dissociated by 
20 min incubation with 0.25 % trypsin. Cells were washes three times with warm 
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HBSS before dissociating the tissue by passing it through a needle 4-6 times. 
Dissociated cells were plated onto poly-D-lysine- or poly(ethyleneimine)- coated 
coverslips at a density of 60.000 cells/cm2 in Dulbecco’s modified Eagle’s medium 
(DMEM) including 10 % foetal calf serum (FCS), antibiotics (100 U/ml penicillin, 
100 μg/ml streptomycin), and 2 mM glutamine. 12 hours after plating, the medium 
was exchanged for Neurobasal including 2 % B27 (Life Technologies), antibiotics, 
and 0.5 mM glutamine.  
HEK293 cells were cultured in DMEM/F-12 (Invitrogen) medium supplemented with 
10 % FCS (PAA, Austria). Cells were plated at 10 % initial confluency onto poly-L-
lysine coated coverslips. cDNA was transfected using Fugene HD (Roche, 
Switzerland) according to the supplier's protocol. Protein expression was allowed for 
16-24 hours prior to conducting experiments. All cells were kept in a humidified 95 % 
air, 5 % CO2 incubator.  
 
3.1.3 Transfection of DIV9 neurons  
Neurons were kept in Neurobasal including 2 % B27 (Thermo Fischer, USA), 
antibiotics, and 0.5 mM glutamine until DIV 9 before magnetofection using 
CombiMag (OZ BIOSCIENCES, France) according to method B of Buerli et al. 
(2007) with some modifications. 0.8 µg cDNA were diluted in 150 µl Neurobasal, 
while in a different reaction cup 7 µl Lipofectamine 2000 (Invitrogen, USA) were 
mixed and incubated for 5 min at room temperature. Both formulations were 
combined and 1 µl undiluted CombiMag (OZ BIOSCIENCES, France). The complex 
was incubated for 15 minutes at room temperature before it was distributed over four 
wells of a 24 well plate. The plate was incubated on a magnetic plate (IBA, Germany) 
at 37° C, 5 % CO2 for 25 minutes before replacing 80 % of the culture medium. 
Expression was allowed for 72 hours. 
 
3.2 Immunocytochemistry 
Cells were fixed with 4 % formaldehyde (Sigma-Aldrich, USA) in PBS, pH 7.4 for 20 
minutes on ice. Permeabilisation was performed using 0.1 % Triton X-100 (Sigma-
Aldrich, USA) in PBS for 5 min. After 10 min blocking with PBS-gelatin (Sigma-
Aldrich, USA) (2 g/L), samples were incubated with primary antibodies (Table 2) over 
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night at 4° C or for 2 hours at room temperature. After four washes with PBS-gelatin 
cells were incubated with secondary antibody as indicated (Table 3). Following two 
washes with PBS/gelatin and two washes with PBS, coverslips were mounted in 
Mowiol 4-88 (Aventis Pharma, Germany) 
 
Table 2: List of primary antibodies
 Primary Antibody Manufacturer Order-No. Dilution 
Anti-mTOR antibody [Y391] 
ab32028 
abcam, GB ab32028 100 
Phospho-mTOR (Ser2448) 













Akt (pan) (C67E7) Rabbit mAb Cell Signaling 
Technology, USA 
#4691 200 
Phospho-Akt (Ser473) (D9E) 










antibody produced in mouse 
Sigma-Aldrich, USA M4439-100UL 1000 
HA.11 Clone 16B12 
Monoclonal Antibody 
Covance, USA MMS-101R 1000 
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Table 3: List of secondary antibodies  
Secondary Antibody Manufacturer Order-No. Dilution 
Cy3-conjugated AffiniPure 
F(ab')2 Fragment Goat Anti-






F(ab')2 Fragment Goat Anti-





AffiniPure Fab Fragment 





AffiniPure Fab Fragment 





AffiniPure Fab Fragment 




Alexa Fluor 647-conjugated 
AffiniPure F(ab')2 Fragment 
Donkey Anti-Guinea Pig IgG 




Alexa Fluor 647-conjugated 







3.3 Antibody labelling with amine-reactive ATTO-labels 
Antibody labeling was performed according to the protocol provided by ATTO-TEC 
with slight changes. 200 µg glycerin-free monovalent Fabs fragment (Table 2) were 
diluted in 200 µl 10mM sodium bicarbonate buffer (pH = 8.3). ATTO 532-NHS ester 
(ATTO-TEC, Germany) was diluted to 10 mM in anhydrous, amine-free DMSO. 
ATTO 580Q-NHS ester was diluted to 10 mM in anhydrous, amine-free DMF. A 3-
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fold molar excess of ATTO dyes was combined with the antibody solution and 
incubated for 30 min protected from light at room temperature. 
Following, the Fab fragments were separated from unbound dye by gel filtration over 
an Econo-Pac 10 DG Disposable Chromatography Column (Bio-RAD, USA). The 
efflux was collected in 1 ml fractions and the absorption of every fraction was 
measured at 280 nm. Antibody-containing fractions were combined and concentrated 
over Amicon ultra centrifugal filter 10 K (Millipore, Germany). A UV-VIS spectrum of 
the concentrated antibody solution was obtained and the degree of labelling was 
determined. 
 
3.4 PCR Cloning 
The P1 isoform (Prior et al., 1992) of rat pEGFP-gephyrin and rat pmCherry-gephyrin 
was obtained from RJ Harvey, University College London. The S200A, S268A and 
S270A mutants were generated by site directed mutagenesis using QuickChange XL 
Site-Directed Mutagenesis Kit (Stratagene, USA) according to the manufacturer 
instructions using specific primers (Table 4). 
 
Table 4: Gephyrin mutant primers 
Primer 
Name 
Sequence (5’ – 3’) 
S200A fwd CTTTCTCCACCTCCTACAACTGCGCCACATAAGCAGACAGAAGAC 
S200A rev GTCTTCTGTCTGCTTATGTGGCGCAGTTGTAGGAGGTGGAGAAAG
S268A fwd CTTAGCACTACTCCTGCAGAGTCGCCCCGTGCC 
S268A rev GGCACGGGGCGACTCTGCAGGAGTAGTGCTAAG 
S270A fwd GCACTACTCCTTCAGAGGCGCCCCGTGCCCAGGCTAC 
S270A rev GTAGCCTGGGCACGGGGCGCCTCTGAAGGAGTAGTGC 
 
 
The cDNA of pRK5myc-CB2SH3- was obtained from the lab of RJ Harvey. HA-tagged 
neuroligin 2 (HA-NL2 in pcDNA3) (S. Jamain, Faculté de Médecine-Hôpital Henri 
Mondor, Créteil, France), gephyrin clustering mutants RER EGFP-gephyrin and 4×R 
EGFP-gephyrin (described in Saiyed et al., 2007) were kindly provided by T. 
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Papadopoulos (Max-Planck-Institut für Experimentelle Medizin, Göttingen). The 
cDNA of EGFP-mTOR and mTOR-EGFP was obtained from Stanley Botchway 
(Central Laser Facility, STFC, Rutherford Appleton Laboratory, Research Complex at 
Harwell, Didcot, Oxon OX110QX, UK.) 
 
3.5 Cloning of C-terminally labelled Gephyrin constructs 
The sequence of rat Gephyrin was amplified by PCR from pEGFP-gephyrin using the 
primer containing restriction sites for Kpn1 and Xma1 below. 
 
Table 5: C-terminally labelled Gephyrin constructs 
 
 
The PCR product and acceptor vectors, pmTurquoise-N1 and pEYFP-N1 (Clonetec), 
were digested with Xma1 and Kpn1 and ligated using the Rapid DNA Dephos and 
Ligation Kit (Roche, Switzerland) according to the manufacturer instructions. The 




Confocal images were taken on a FluoView1000 (Olympus, Japan) equipped with a 
60×NA 1.35 UPLS-Apo objective (Olympus, Japan). mTurquoise, EGFP and EYFP 
were excited with the 456 and 515 nm lines of an Argon laser (company, country); 
the emission was separated by an 458 dichroic mirror. EGFP and mCherry and were 
excited with a 559 nm line of laser diode (NTT electronics, Japan); Alexa647 and Cy5 
were excited with the 640 nm line of laser diode (Olympus, Japan), respectively. 
Fluorescence lifetime images were recorded using a pulsed laser diodes of 440 nm, 
485 nm and 532 nm driven by a Sepia II unit (Picoquant GmbH, Berlin Germany) at a 
repetition rate of 40 MHz (Picoquant GmbH, Berlin, Germany). Fluorescence was 
Primer name Primer sequence (5’ – 3’) 
GPHN-Kpn1-fwd 5'-TAAGCAGGTACCATGGCGACCGAGGGAATGAT-3' 
GPHN-Xma1-rev 5'-TGCTTACCCGGGATAGCCGTCCGATGACCATGAC-3' 
Materials and Methods 
	
	 50
reflected on a PDM series single photon avalanche diode (Picoquant GmbH, 
Germany). 
 
3.7 Image Analysis, Quantification and Representation 
Images in PT3 format were converted into ICS format (Dean et al., 1990) using 
PTC2ICS software (Geert van den Bogaart). ICS files were analysed using TRI2 
software version 2.8.5.1 (PR Barber, RJ Locke, RJ Edens, SM AmeerBerg, B 
Vojnovic, GP Pierce, and M Rowley). The images were thresholded by intensity in 
TRI2 before all counts represented in phasor plot. Distributions of monoexponential 
lifetimes were derived from Phasor plots. The distributions were normalized to unity 
averaged and fitted to Gaussian distributions in GraphPad prism version 5.01.  
 
Statistics 
To determine difference between conditions, the standard error of the mean was 
used to calculate p-values. Due to the fact that nearly every observed difference 
between conditions of an experiment was significant with a value of p < 0.0001, p 
values are not represented in the figures. The use of the standard error of the mean 
was indicated, the lifetime of a fluorophore is not a subject of population variance. 




To generate FRET pictures the inverted look up table was applied to the lifetime 
images in a before set lifetime range. The pictures were exported from TRI2 in TIFF 
format and converted into RGB format using ImageJ software (version 1.47, Wayne 
Rasband). The RGB format was converted and into HSB stack in which the B layer 
was replaced by the intensity image of that same picture. The HSB stack was then 






4.1 Establishment of antibody-based phosphorylation assays 
Posttranslational modifications, like phosphorylation or acetylation, are fast signalling 
events that sustain or change the signalling properties of molecules within the cell. 
Hence, they can be used as markers for signalling states. 
mTOR is phosphorylated at S2448 when the cell is in a state of growth and glucose, 
amino acids and growth factors are in sufficient supply. mTOR sustains translation by 
being assembled in mTORC1, which phosphorylates S6K1/2 and E4-BP1 to initiate 
mRNA translation. Rapamycin or insufficient supply of amino acids, glucose or 
growth factors inhibits mTORC1 and terminates mRNA translation (Laplante and 
Sabatini et al., 2012). 
Phosphorylation-specific antibodies are indispensable tools in biochemistry to assess 
the phosphorylation states of proteins. Standard techniques to detect 
phosphorylation levels include lysis of large number of cells which are then subjected 
to gel electrophoresis, blotting and subsequent detection with antibodies. This 
technique can be used to roughly estimate the average phosphorylation of a given 
protein. All cell type-specific or cell state-specific aspects of phosphorylation events 
like oscillations are averaged. 
Most signalling molecules including mTOR and Akt show distinct cellular localisations 
depending to their signalling state. It is therefore necessary to connect the 
phosphorylation status with spatial information to fully comprehend their function. 
Other approaches utilise phosphorylation-specific binding motives like SH3 domains 
coupled to fluorescent molecules to detected changes in phosphorylation states. 
They can be used in live cells to analyse dynamic signalling processes. 
Nevertheless, these domains introduce functional entities that have the capacity to 
interfere with the events that they are supposed to report on. 
A more quantitative way to measure the phosphorylation states are 
immunofluorescence-based ratiometric assays. To this end, two antibodies are used 
to quantify the total protein and the phospho-epitope. The relative phosphorylation 
level is obtained from determining the ratio of fluorescence intensity of the individual 
labels. The advantage of this method is that it can be used to analyse endogenous 
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signalling events without the use of exogenous reporter molecules. The major 
disadvantage of this type of assay is that it depends on the quality of the antibodies. 
The ratio may also amplify unspecific signals, veiling physiological effects. 
One way to manage the disadvantages of antibody-based assays is the use of FRET 
as a “clean-up” method. The energy transfer process between donor and acceptor 
molecules rely on the extremely short-ranged interactions of fluorophore dipoles. The 
efficiency of energy transfer drops from “all” to “nothing” within a few nanometres. If 
FRET can be measured between antibodies directed against adjacent epitopes, it is 
highly likely that both antibodies have bound their specific targets. Hence; FRET can 
be used to evaluate the specificity of an antibody. Given the distance-dependence of 
FRET, binding to unspecific targets, would not generate a FRET signal. In 
fluorescence lifetime microscopy, unspecific binding ads to the non-FRET portion 
which has the potential to dilute the FRET signal but will not generate false-positive 
FRET. 
 
4.1.1 Antibody choices 
Commercially available antibodies were selected on the basis of: 
1. Applicability in immunofluorescence experiments 
2. Location of the epitope in the amino acid sequence 
3. Target and host species 
4. Popularity (number of application-relevant publications) 
The C-terminal portion of mTOR was chosen as target epitope because it appeared 
most likely to come in close proximity to the S2448 epitope. The criteria listed above 
were only met by two antibodies: anti-mTOR antibody [Y391] from abcam 
(Cambridge, England) and mTOR (7C10) Rabbit mAb from Cell Signaling 
Technologies (Cambridge, England). Both antibodies were used for all following 
experiments. They will be referred to as “abcam” and “7C10” hereafter.  
Amongst the antibodies directed against phosphorylated S2448, two antibodies were 
chosen: “phospho-mTOR (S2448) (49F9) Rabbit mAb (IHC specific)” and “Phospho-

















































































In 2012, when these experiments were conducted, mTOR was considered to be 
localised in the cytoplasm. The first reports about a lysosomal localization of 
mTORC1 were published in 2010 (Sancak et al. 2010) but only later in 2013 a 
recruitment of mTORC1 components to endosomal or lysosomal membranes was 
confirmed (Zhou et al. 2013). The cytoplasmic staining pattern was therefore 
preferred over the granular staining pattern. 
Several components of mTORC1 including mTOR have been reported to have 
nuclear localization (Kim and Kahn 1997; Kim and Chen 2000; Zhang et al., 2002; 
Kikani et al., 2005; Liang and Di Cristofano, 2005; Rosner et al., 2007; Rosner and 
Hengstschläger, 2008; Rosner and Hengstschläger, 2012). These two observations 
lead to the conclusion that the diffuse cytoplasmic and bright nuclear staining 
patterns observed with the abcam and the IHC-specific antibodies had to be correct. 
Both antibodies were therefore used in the following FRET experiments.  
	
4.1.2 Assay considerations 
A phosphorylation assay is supposed to report on the portion of total protein that is 
phosphorylated. In donor based FRET measurements the total protein should be 
labeld the donor fluorophore because it is likely to be constant. The phosphorylated 
epitope should be labelled the acceptor because it may vary dynamically which 
would lead to high FRET efficiencies at high phosphorylation levels and low FRET 
efficiencies at low phosphorylation levels. If the phospho-epitope was labeld donor, 
the signal may be lost at low phosphorylation levels which would render the assay 
unmeasurable. 
The chosen antibodies were all raised in rabbit. Consequently, the FRET assay 
required a sequential application of the primary antibodies. It was therefore to be 
answered which antibody should come first. Phosphorylation-specific antibodies 
usually have lower affinities than antibodies directed against unphosphorylated 
targets. Therefore the total mTOR antibody was applied first because it seemed more 
likely to endure repeated washing. Experiments in which the pS2448 was used first 
confirmed this assumption (data not shown). 
With two antibodies from the same spiecies a certain amount of cross-reactivity had 






















































































































































cross-reactivity with Cy5-conjugated F(ab)2-fragments is 100 ps or 6.27 % FRET. 
Cross-reactivity creates a significant offset in this assay. Consequently, the cross-
reactivity control was used as reference point in order to calculate the relative FRET 
efficiency. The relative increase in FRET efficiencies by the interaction of the two 
labeled mTOR epitopes was measured 9.7 %. The highest FRET efficiencies were 
observed in the nucleus and in the cytoplasm, reaching up to 25 %. The prominent 
bright puncta that are observed throughout the cytoplasm in the intensity image did 
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4.1.3 FRET optimisation 
FRET assays need to be optimized in respect to application and measurement 
requirements. We use TCSPC FLIM, a technique with the highest achievable 
accuracy and sensitivity among all FRET techniques. The high precision is achieved 
by a high number of collected photons, which can be provided by long recording 
times or high photon count rates. Therefore, fluorophores photostability and 
brightness become important characteristics. 
Cy3 has moderate relative brightness but low photostability, which limits its 
application for TCSPC FLIM experiments. We therefore searched for alternatives 
with a similar emission profile. 
ATTO 532 has similar extinction coefficient at 532 nm but a higher photostability than 
Cy3 and most importantly a 6-fold higher quantum yield. ATTO 532 was therefore 
considered as a potential substitute for Cy3 which was tested subsequently by direct 
comparison (Figure 11). 
ATTO 532’s longer lifetime of 3.2 ns (conjugated) is beneficial for FRET as it 
increases the dynamic range of the measurement. The same relative increase in 
FRET efficiencies of 10 % results a larger relative changes of the lifetimes. 
Under half assay conditions, the lifetime of ATTO 532 is 2.8 ns (SD: 0.21 ns). The full 
assay shows a lifetime of 2.5 ns, which corresponds to 11.91 % FRET (SD: 7.3 %). 
In comparison, the Cy3/Cy5-based mTOR assay shows a FRET efficiency of only 8.8 
% (SD: 9.6 %). The increased FRET efficiency and the lower SD are desirable 
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It was therefore tested if replacing ATTO 580Q for Cy5 is beneficial. ATTO 580Q is a 
fluorescence quencher that will absorb energy without emitting photons. This allows 
recording of the donor fluorescence over a wider spectral range or to re-use the 
acceptor spectral window for detecting cellular markers. The combination of FRET 
assays with molecular markers for biological structures adds substantial information 
for understanding localized signalling events. 
ATTO 532 with Cy5 shows a mean lifetime of 2.9 ns (SD: 0.17 ns) under half assay 
conditions and 2.46 ns (SD: 0.15 ns) under full assay conditions. The lifetime 
difference of 430 ps corresponds to a FRET efficiency of 14.73 % (SD: 5.24 %). 
When combined with ATTO 580Q the lifetime of ATTO 532 was measured as 2.77 ns 
(SD: 0.15 ns) under half assay conditions and 2.2 ns (SD: 0.15 ns) under full assay 
conditions. The lifetime difference of 570 ps corresponds to a FRET efficiency of 
20.66 % (SD: 5.26 %) which represents an increase of nearly 6 % FRET. This data 
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We suspected that the IHC-specific antibody did not faithfully displays the 
phosphorylation level of mTOR. We therefore selected a new antibody and tested its 
phospho-selectivity by a semi-quantitive immunofluorescence experiment. It was 
tested if the phosphorylation-specific antibody D9C2 termed “XP” could detect 
changes in the phosphorylation of mTOR. To this end, HEK293 cells were treated 
with rapamycin for 30 min and stained with XP-ATTO 532. The relative ATTO 532 
fluorescence intensity was measured on a wide-field microscope using constant 
illumination and acquisition times. The fluorescence intensities were normalized to 
unity and averaged over 20 fields of view. The results are displayed in Figure 14 A. It 
shows that rapamycin reduces the intensity of the XP signal, which confirms that the 
antibody detects reduced phosphorylation levels of mTOR. Consequently, the IHC-
specific antibody was replaced by the XP antibody. 
Following, it was tested if the XP antibody exhibits FRET with the abcam total mTOR 
antibody (figure 14 B). To this end, the XP was directly compared to the IHC-specific 
in the Cy3/Cy5-based mTOR assay. The side by side comparison showed that the 
XP antibody exhibits 8.7 % FRET (SD: 7.7 %) compared to 4.9 % FRET (SD: 8.3 %). 
It was next tested if the mTOR assay using the XP antibody would detect changes in 
mTOR phosphorylation as induced by rapamycin or insulin. Yet again, the assay 





























































































































































































4.1.5 Monovalent Fab fragments in antibody-based FRET assay 
The only single-domain antibodies, commercially available at the moment, are 
camelid single domain antibodies (sdAb, also marketed as nanobodies) and 
monovalent Fab fragments. Camelids produce antibodies with antigen binding 
domains consisting only of a variable heavy chain (VHH domain). The VHH domain 
represents a 12-15 kDa immunogenic fragment with full antigen binding capacity. In 
comparison, monovalent Fab fragments derived from IgGs are 55 kDa in size. Due to 
their lower size nanobodies allow higher labelling densities than Fab fragments. 
However, at the time that these experiments were executed, this technology was new 
and nanobodies directed against mTOR, pS2448 or primary rabbit antibodies were 
not available. The custom design of nanobodies involves the immunization of Lamas 
and subsequent genetic screenings, which costs time and money. In contrast Fab 
fragments are an established technology, well studied, easily available and cheap. 
Hence, monovalent Fab fragments were conjugated to ATTO 532 or ATTO 580Q and 
used as secondary antibody in the phosphorylation assay. The labelling ratio was 
determined as 0.95 or 1.17 labels per Fab fragment. As there was no experience in 
the use of monovalent Fab fragments, the first step was to determine the optimal 
antibody dilutions. To this end HEK293 cells were stained with anti-mTOR 7C10 and 
different dilutions of ATTO 532-conjugated Fab fragments. The relative intensity and 
lifetime of ATTO 532 was determined by FLIM. At higher antibody concentrations, the 
fluorescence intensity was higher and the standard deviations of the recorded 
lifetimes smaller. This may be due to autofluorescence that is contributing more to 
the overall signal at low antibody concentrations. A good signal-to-noise ratio was 
obtained at a dilution of 1:200. 
In order to determine the cross-reactivity between the Fab fragments, the ability to 
infiltrate an already existing Fab decoration was tested. To this end, mTOR was 
stained with ATTO 532-conjugated Fab fragments at 1:200 and was subsequently 
incubated with differing dilutions of ATTO 580Q-conjugated Fab’s. The results show 
that ATTO 580Q-conjugated Fab’s penetrate the preexisting ATTO 532 decoration at 
every dilution tested. At 1:500 the compromise between labelling and cross-reactivity 
appeared to be optimal. 
In the opposite configuration the competition between ATTO 532-conjugated Fab 
fragments and an existing ATTO 580Q-Fab decoration was tested. As in the previous 
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experiment, the binding of ATTO 532-Fab's is increasing proportionally with its 
concentration. At concentrations higher than 1:100 the ATTO 532-Fab starts to 
penetrate the ATTO 580Q-Fab decoration more efficiently. It was therefore decided 
to use ATTO 532-Fab fragments at a dilution of 1 in 200 or lower (Data not shown).		
	
4.1.6 Physiological evaluation of the mTOR assay 
After defining antibody dilutions, cross-contamination and staining sequence with the 
new conjugated Fabs, the physiological responsiveness was to be evaluated. 
HEK293 cells were stained with thte XP antibody in combination with the 7C10 or the 
abcam (Figure 16). For comparability, both experiments were performed in parallel. 
The 7C10 antibody showed the already described granular staining pattern with 
mTOR beeing localized to intracellular membranes. The mean FRET efficiency of the 
full assay is 5.0 % (SD: 2.48 %). The administration of rapamycin for 1 hour reduces 
the FRET efficiency to 2.7 % (SD: 2.4 %). The granular structures that are localised 
closely behind the leading edge of the cell seem to react stronger to rapamycin than 
the more central ones. This is in agreement with the literature (Sancak et al. 2010; 
Zhou et al. 2013) 
When the mTOR assay is performed with the abcam antibody the staining pattern 
shows a strong nuclear localisation (Figure 6). The localisation of mTOR in the 
cytoplasm and the plasma membrane is consistent with the 7C10 staining. The 
unstimulated cells show FRET efficiencies of 8.8 % (SD: 2.3 %). The administration 
of rapamycin reduced the FRET efficiency to 7.7 % (SD: 2.1 %). The response to 
rapamycin is strongly inhomogeneous with reduced FRET efficiencies in the 
cytoplasm while the nuclear signal remained unchanged. This suggests that the 
nuclear localisation observed with the abcam antibody may originate from unspecific 
binding to a different target that shows nuclear localisation. The 7C10 was therefore 












From the data in Figure 14 it was known that the XP does react to rapamycin in a 
semi-quantitative assay. On the other hand, it was also known that the IHC-specific 
failed yet to respond to physiological stimulations. In order to verify this, both 
antibodies were compared side by side in the mTOR assay (Figure 17). As in the 
previous Figure the XP antibody showed approximately 5 % (SD: 1.6 %) FRET 
efficiency. When mTORC1 was inactivated with rapamycin, the FRET efficiency was 
reduced to 0.5 % (SD: 2.4 %). In the previous experiment the reduction was smaller 
here maybe because a lower concentration (1:500) of ATTO 532-Fab fragments was 
used. 
In comparison, the IHC-specific antibody gave a higher mean FRET efficiency of 8.7 
% (SD: 1.3 %). But rapamycin reduced the FRET efficiencies only to 6.0 % (SD: 2.7 
%). The residual FRET was consistently located to the perinuclear region as well as 
to protrusions and ruffles of the plasma membrane while the cytoplasmic FRET 
signal was consistently reduced. The XP antibody seemed therefor to be more 
specific than the 'IHC-specific' in detecting changes of mTOR phosphorylation and 
was therefore used in all following experiments. 
The mTOR phosphorylation assay, as it was established here uses a staining 
procedure starting with the pS2448 (XP) which is decorated with an ATTO 580Q-
conjugated monovalent Fab fragment at a dilution of 1:200. Total mTOR is detected 
by the 7C10 antibody and decorated with an ATTO 532-conjugated monovalent Fab 
fragment at a dilution of 1:500. The previous experiments demonstrated that 
antibody-based FRET assays can be established even if both primary antibodies are 
raised in the same species. By using monovalent Fab fragments the cross-reactivity 
could be controled. Moreover, the here presented results demonstrate how crucial 












4.1.7 mTORC1 signalling in MeCP2-KO neurons 
The mTOR assay was designed to allow for analysis of mTORC1 activity on single 
cell level. This was supposed to be applied to MeCP2-KO neurons in order to identify 
potential sub-populations of brain cells that show reduced mTORC1 activity. 
Neuronal cell cultures of the hippocampus of MeCP2-KO mice and WT littermates 
were prepared and fixed at DIV7. The mTORC1 assay was applied according to the 
procedure described in previous experiments.  
The staining shows that mTOR is localised in the cytoplasm with a very pronounced 
staining in the soma, dendrites and axons. The granular localisation is less 
pronounced in neurons than in HEK293 cells. As observed in HEK293 cells, the 
nucleus does not contain any mTOR signal. The phosphorylation assay shows that 
mTORC1 activity varies strongly between cells. Neurons appear to have higher 
phosphorylation than smaller cells that appear to be glia. Hippocampal neurons from 
MeCP2-KO mice show the same mTOR localization as WT but the overall 
phosphorylation level is significantly reduced (2.5 % SD). Cells that, on the basis of 
their morphology are judged to be neurons, show very low FRET efficiencies and are 
smaller, show less dendritic arborisation and thinner axons than in the WT 
preparation. Cells with glia appearance have higher FRET efficiencies than most 
neurons in preparations from MeCP2-KO mice. The overall fitness and viability of 
MeCP2-KO neurons was judged lower than of WT neurons (Figure 18). A higher 
number of dead cells and a lower neuron to glia ratio were observed, which taken 
together may suggest a neuron-specific reduction of mTOR phosphorylation leading 
to decreased cell viability. These findings are in line with a study from Ricciardi et al. 
(2011) that showed reduced S2448 phosphorylation and reduced S6K1 activity in 
brain lysates of MeCP2-KO mice. 
The lifetime distributions under half assay conditions show a difference between WT 
(2.5 ns) and MeCP2-KO (2.35 ns) even though the assay conditions are the exact 
same. Cross-reactivity is, as long as the number of epitopes is the same, a mere 
function of the concentrations of the two secondary antibodies. Here the antibody 
concentrations were the same. Hence the lifetime difference under 'half assay' 
conditions may be due to changes in the number of epitopes. The reduced lifetime in 
MeCP2 may reflect a lower mTOR expression as a direct effect of MeCP2 

























4.2 Development of an mTORC2 activity assay 
Much effort has been put into elucidating the signalling pathways linked to mTORC1. 
Many upstream activators and downstream effectors have been identified and 
characterized. They make up a complex signalling network that mTORC1 is 
embedded in. 
In contrast to mTORC1, very little is known about mTORC2. It is activated by insulin, 
growth factors and nutrients and regulates the activity of Akt and PKCα. 
The activation mechanism of Akt includes its recruitment to the plasma membrane, 
where it is phosphorylated by PDK-1 at T309. This renders Akt active, but it needs 
phosphorylation at S473, executed by mTORC2, to fully activate Akt. Akt activates 
mTORC1 by inhibiting phosphorylation of TSC2, Pras40 and GSK-3β. The 
phosphorylation of Akt at S473 seems to be exclusive to mTORC2. Consequently 
this phosphorylation can conveniently be used as a measure for mTORC2 activity. 
Analysing this phosphorylation event tells us two things, first: the activity state of Akt 
itself, and second: that of the executing kinase complex, mTORC2. 
As for mTORC1, the most direct way to optically analyse endogenous mTORC2 
activity without introducing genetic sensors was by phosphorylation-specific 
antibodies. This time the mTORC2 substrate, Akt was chosen as epitope because 
there weren’t any good antibodies against mTORC2 subunits available that would 
show FRET (Data not shown). The best antibodies against Akt according to the rules 
from section 4.1.1 were raised in rabbit. The experience made with the mTORC1 
assay, could therefore be use in the mTORC2 assay (Figure 19). 
The phosphorylation-specific antibody shows a staining that is most prominent at the 
plasma membrane. The cytoplasm and the nucleus show lower intensities. The total 
Akt signal shows the same staining pattern with a slightly less pronounced 
membrane localisation in unstimulated cells. Both localisation patterns are in line with 
the activation process of Akt. 
The phosphorylated S473 was stained with ATTO 532-conjugated Fab fragments 
and total Akt was stained with ATTO 580Q-conjugated Fab fragments. The epitopes 
of the total-Akt antibody and pS473-Akt antibody are located closely together in the 
amino acid sequence of Akt. Should the antibodies exhibit steric hindrance in the 
recognition of the epitopes, it is beneficial to first include the acceptor labelled 
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antibody. This way, at least all pAkt epitopes are labelled. This is essential for 
allowing maximal FRET efficiencies. 
The mean FRET efficiencies in unstimulated cells is 15.3 % (SD: 5.1 %). Upon 
stimulation with 6.6 nM insulin, high signals from pS473-Akt are detected at the 
plasma membrane while the administration of LY294002, an inhibitor of PI3K leads to 
a complete loss of the pS473-Akt signalall over the cell. This confirms the high 
specificity of the pS473 antibody. The FRET efficiencies decrease by stimulation with 
insulin (12.9 %, SD: 4.6 %) and increase considerably by inhibition with LY294002 
(23.9 %; SD: 5.0 %). This inversion of the FRET signal is caused by the fact that the 
phosphorylation-specific antibody was labelled with the donor fluorophore (see 
section 4.1.2). The inhibition of Akt phosphorylation abrogates the binding of the 
phosphorylation-specific antibody. Consequently, the donor signal is nearly lost, 
which results in very low donor-acceptor ratios, which favour high FRET efficiencies. 
In contrast, when phosphorylation of Akt is stimulated by insulin, the FRET efficiency 
is decreased although Akt is visibly activated, as judged by the massive membrane 
recruitment. This recruitment results in an increase in the donor-acceptor ratio which 













The inverted response was considered not favourable for an Akt activity assay. 
Therefore, the donor and acceptor labels were switched. Total Akt was now labelled 
with the donor and pS473-Akt was labelled with the acceptor (Figure 20). In the 
switched configuration unstimulated cells show a mean FRET efficiency of 4.3 % 
(SD: 3.9 %) with high FRET efficiencies of up to 12 % located in membrane ruffles. 
Akt signal coming from the nucleus showed low FRET efficiencies. The stimulation of 
Akt with insulin resulted in a strong recruitment of Akt to the plasma membrane 
where it shows the highest FRET efficiencies of up to 16 %. The mean FRET 
efficiency is increased by 46 % to 6.3 % (SD: 3.8 %). In contrast, the inactivation of 
PI3K resulted in a complete loss of membrane-bound Akt and a global loss of FRET 
(E = -0.3. %; SD: 4.3 %). These results are in agreement with the already described 
activation mechanism of Akt and show that the inverted design permits sensitive 












mTORC2 was first reported to be a rapamycin-insensitive second mTOR complex 
(Sarbassov et al., 2004). As a potential cancer therapeutic rapamycin could reduce 
mTORC1 signalling without interfering with mTORC2. 
Later a cell-type dependent rapamycin-sensitivity to chronic rapamycin administration 
was described by the same authors (Sarbassov et al., 2009). A potential interfering 
with both mTOR complexes was considered to be disadvantageous for a potential 
cancer therapy as it could lead to uncontrolled cell death. One of the described cell 
types with a reported partial rapamycin-sensitivity of mTORC2 was HEK293. It was 
therefore tested if rapamycin-sensitivity of mTORC2 could be reproduced by long-
term administration. HEK293 cells were treated with 100 nM rapamycin for 1, 24 or 
48 hours and Akt phosphorylation was assayed (Figure 21). The results show that 
rapamycin does not interfere with the phosphorylation of Akt by mTORC2 as 
indicated by the FRET efficiency images and distributions. Rapamycin even seems to 
increase the membrane recruitment of Akt, leading to a significant increase of Akt 
phosphorylation after 48 hours from 9.7 % (SD: 2.6 %) to 11.2 % (SD: 2.3 %) FRET. 
The increase in Akt phosphorylation can be explained by an mTORC1-dependent 
negative feedback mechanism: active mTORC1 effector protein S6K can initiate the 
sequestration of insulin receptor substrate, an upstream co-activator of the PI3K-Akt-
mTOR pathway. With rapamycin inhibiting this mTORC1-dependent negative 
feedback mechanism, IRS is enriched at the plasma membrane which fuels the 












4.2.1 Application of the Akt phosphorylation assay to MeCP2-KO 
neurons. 
The reduced activation of mTORC1 in neurons derived from MeCP2-KO mice 
indicates a compromised activation of the PI3K-Akt-mTOR pathway. In neurons, 
BDNF activates this pathway by binding to the TrkB receptor. It has been reported 
that BDNF translation, transport and secretion is reduced in MeCP2-KO mice (Li and 
Pozzo-Miller; 2014). To test if mTORC2 activity is reduced in neuronal cultures 
derived from MeCP2-KO mice, Akt phosphorylation was assayed as established 
before. In mouse neurons, the Akt staining is located to the plasma membrane and 
the cytoplasm, with highest intensities located in the soma and major axonal and 
dendritic protrusions. Relative Akt phosphorylation is homogeneous throughout 
different cell types and cellular regions (5.1 % FRET; SD: 2.2 %). In MeCP2-KO 
neurons, the mean FRET efficiency is reduced to 2.8 % (SD: 3.0 %). Like in the 
mTOR assay, shorter lifetimes were observed under half assay conditions (WT 2.5 
ns; MeCP2-KO 2.3 ns) They indicate a reduced level of Akt expression in MeCP2-KO 
neurons compared to WT. This result is similar to the observation that mTOR 
expression is reduced in MeCP2-KO neurons. An intriguing possibility would be that 
a negative feedback mechanism exists by which reduced expression of BDNF results 
in reduced activation the PI3K-Akt-mTOR signalling pathway which in turn reduces 












4.3 A FRET-based mTOR-gephyrin interaction assay 
In 1999, Sabatini and colleagues reported a direct interaction of mTOR and gephyrin 
with functional implications for mTORC1 signalling. Mutants of mTOR, that were 
unable to bind gephyrin also failed to activate their downstream targets S6K1 and 
4E-BP1. These findings placed mTOR dependent mRNA translation into the context 
of inhibitory synapse formation, maturation, and plasticity. One major obstacle to 
define the role of mTOR and gephyrin interaction at inhibitory postsynaptic sites is 
that both molecules are ubiquitously expressed throughout all cell types. It was 
therefore indicated to create an optical assay that reports on the interaction of mTOR 
and gephyrin with spatial resolution. For this purpose, EGFP- and mCherry- fusion 
constructs of mTOR and gephyrin were co-expressed and FRET was measured by 
TSCPC-FLIM.  
First, it was tested whether EGFP fused to mTOR at the C- or N-terminus results in 
FRET with mCherry-gephyrin. To this end, both proteins were co-expressed in 
HEK293 cells. Neither the C- nor the N-terminal fusion construct of mTOR showed 
FRET with mCherry (data not shown). This finding indicated that the gephyrin binding 
site within mTOR is too far away from either ends of mTOR for FRET to occur. This 
is in line with the reported gephyrin binding site being located to the distal portion of 
the HEAT domain with isoleucine 1034 being crucial for gephyrin binding (Sabatini et 
al., 1999). 
It was therefore tested if an antibody labelling would increase the chance of FRET. 
Antibody labelling can be used to mitigate the extreme distance dependence of 
FRET. As already described, a full IgG has a diameter of around 10 nm and F(ab)2 
fragment is 5 nm in diameter. The FRET range can be extended by a theoretical 
maximum of 15 nm. Additionally, an antibody labelling with polyclonal secondary 
antibodies creates an unstructured cloud of fluorophores which reduces the 
orientation dependence of FRET. The 7C10 antibody was used to label the distal 
portion of mTOR. It was labelled with ATTO 580Q-conjugated F(ab)2 fragments. 
FRET was measured by determining the lifetime of mCherry-gephyrin. EGFP-mTOR 
and mCherry-gephyrin were co-expressed in a 1:1 molar ratio and the lifetime of 
mCherry was measured with or without the mTOR-ATTO 580Q antibody labelling. 
mCherry-gephyrin exhibits both a cytoplasmic and a sub-membranous expression. It 
was never detected in the nucleus. At higher expression levels gephyrin forms large 
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amorphous intracellular aggregates that are of globular or amorphous shape. Since 
large aggregates like these are not reported to exist in neurons, they are considered 
to be overexpression artefacts and were excluded from the measurements. The 
abundance of gephyrin aggregates was found to be directly dependent on the 
amount of cDNA transfected as well as the duration of expression. These parameters 
were optimized for the reduction of gephyrin aggregation in our experiments. For the 
measurement of the mTOR-gephyrin interaction, only cells without aggregates were 
chosen. The intensity and the corresponding FRET efficiency images of gephyrin are 
shown in Figure 23. Without antibody staining, no FRET could be detected. Cells 
stained with mTOR-ATTO 580Q display a mean FRET efficiency of 13.5 % (SD: 2.6 
%). The interaction appears to be homogeneous throughout the cytoplasm. There 
are regions with granular staining that are likely to represent mTOR-positive 
intracellular membranes that are also observed in staining with the 7C10 antibody. 
The ability to measure the interaction between gephyrin and mTOR raised the 
question to which mTOR complex gephyrin binds to. Sabatini and colleagues also 
addressed this question but could not show a reduced interaction when mTORC1 
was disrupted with rapamycin. Instead, they used indirect evidence by showing a 
reduced activity of S6K1 and 4E-BP1 in cells that expressed mTOR mutants that did 
not bind to gephyrin.  
It was therefore tested if the pharmacological inhibition of mTORC1 and mTORC2 
has an impact on association with gephyrin. To this end, rapamycin, a specific 
mTORC1 inhibitor, or LY294002, an inhibitor of mTORC1 and 2, was applied to cells 
expressing EGFP-mTOR and mCherry-gephyrin. Figure 23 shows that rapamycin 
efficiently reduced the interaction between mTOR and gephyrin from 14.3 % FRET to 
9.6 % (SD: 2.4 %) FRET. Administration of LY294002 resulted in the same reduction 
(8.9 % SD: 2.5 %). This result indicates that gephyrin interacts exclusively with 












Gephyrin has been reported to be highly phosphorylated with over 20 
phosphorylatable serine residues located within its C-domain. In recent reports, some 
phosphorylation sites could be connected to kinases: i.e. ERK1/2 at S268 and CDK5, 
and GSK-3β at S270. Moreover, Pin1 has shown to interact with phosphorylated 
S200. 
Alanine exchange mutations of S200, S268 and S270 were introduced into mCherry-
gephyrin and analysed for their interaction with EGFP-mTOR. 
The ectopic expression of gephyrin mutants did not change the localization of 
gephyrin or the morphology of the cell. The analysis of the interaction with mTOR 
revealed that the S200A as well as the S268A showed comparable FRET efficiencies 
with WT gephyrin. The gephyrin mutant S270A, however, showed reduced 
interaction with mTOR. This result indicates that S270 is involved in the interaction 
between mTOR and gephyrin (Figure 24). It also shows that this phosphorylation site 
is likely to be phosphorylated in a state of cellular growth as the exchange mutant 
would not have had any effect. The third conclusion that can be drawn from this and 
the previous experiment is that the interaction between mTOR and gephyrin is multi-













4.4 FRET-based analysis of gephyrin clustering 
Gephyrin is the major scaffolding molecule of the inhibitory postsynapse and thought 
to cluster in a highly ordered process via its G- and E-domains. The G-domains form 
trimers while the E-domains form dimers. Both processes together give rise to a 
hexagonal lattice structure which is thought to organise the inhibitory postsynaptic 
membrane. Most studies on gephyrin cluster formation measure the interaction of 
isolated single G or E domains that were expressed in E.coli. However, eukaryotic 
proteins expressed in bacterial expression systems lack all post-translational 
modifications due to the absence of the enzyme machinery exerting these 
modifications. Gephyrin is known to be a highly phosphorylated protein and its 
aggregation process seems to be regulated by post-translational modifications and 
involves the interaction of the G-, E- and C-domain. It is therefore indicated to study 
the clustering of full length gephyrin in eukaryotic cells, preferably in neurons. 
The analysis of oriented interaction events is a forté of FRET assays due to its 
extreme distance dependence. 
The oriented clustering of gephyrin was analysed by two separate FRET assays, the 
first for the trimerisation of the G domains and the second for the dimerisation of E-
domains. For the trimerisation assay, N-terminally labelled EGFP-gephyrin was co-
expressed with with N-terminally labelled mCherry-gephyrin in a 1:3 molar ratio and 
FRET was measured by determining the lifetime of EGFP by TCSPC-FLIM. Only 
cells without visible gephyrin aggregates were selected for imaging. Small 
aggregates were thresholded by their high intensity. 
Upon co-expression with mCherry-gephyrin, the lifetime of EGFP-gephyrin was 













From the previous experiments analysing the interaction of mTOR and gephyrin, it 
was known that gephyrin interacts with active mTORC1. It was therefore tested if 
mTORC1 inhibition had any effect on gephyrin trimerisation. The FRET efficiency 
increased upon mTORC1 inhibition with rapamycin to 8.9 % (SD: 1.4 %) which is an 
increase of nearly 60 %, indicating that mTORC1 interaction with gephyrin exerts a 
strong negative effect on gephyrin clustering. 
Next, it was next tested how clustering-impaired mutants of gephyrin influence the 
formation of gephyrin trimers. To this end, the trimerisation-impaired mutant '4×R' 
and the dimerization-impaired mutant 'RER', were tested for there effect on 
trimerisation. In the 4×R mutant, four hydrophobic residues located at the 
trimerisation interface are replaced by R (F90R, L113R, L128R and L168R) which 
results in reduced trimer formation. In the optical gephyrin trimerisation assay, this 
mutant strongly impeded trimer formation when expressed together with WT 
mCherry-gephyrin (WT: 6.8 %, SD: 2.0 %; 4×R: 2.1 %, SD: 2.0 %). In the 
dimerisation-mutant RER, three amino acids within the dimerisation interface were 
replaced by arginine or glutamic acid residues (G483R, R523E, A532R). 
Interestingly, the dimerisation-impaired mutant impeded the trimerisation as well, 
since the measured FRET efficiencies were reduced to 3.5 % (SD: 2.3 %). This result 
could mean two things, either the E-domain is involved in the trimerisation of the G-
domains or, there is connection between interdependent pools of gephyrin 
monomers, trimers and the lattice. If the lattice formation is impeded, high 
concentrations of trimers favour the disassembly into gephyrin monomers like in 
coupled equilibrium reactions. This result also answers the question about the state 
that gephyrin is in when expressed in HEK293 cells. It apparently forms the 
hexagonal lattice spontaneously and without the facilitation by synaptic adhesion 
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The formation of the hexagonal lattice from trimeric building blocks involves the 
dimerisation of E-domains. To analyse this process, C-terminally labelled 
mTurquoise- and EYFP-fusion constructs of gephyrin where generated and co-
expressed at a 1:2 molar ratio. The localization pattern of gephyrin-mTurquoise was 
similar to that of EGFP-gephyrin. The measured mean FRET efficiency between 
gephyrin-mTurquoise and gephyrin-EYFP was 4.4 % (SD: 2.6 %). When co-
expressed with constitutively active CB2 or NL2 two FRET efficiencies more than 
doubled to 11.5 % (SD: 4.0 %) or 11.1 % (SD: 3.1 %) with CB2or NL2 respectively. 
This dramatic increase of 161 % suggests that dimerisation of gephyrin E-domains is 












4.5 Gephyrin trimerisation in GABAergic postsynapses 
Gephyrin clustering seems to be a regulated process which depends on the 
molecular composition of the inhibitory post-synapse. Among the determinants, 
subunit compositions of GABAA-receptors, as well as the abundance of CB2 and 
NL2, were identified to play a role. It was therefore tested if gephyrin clustering could 
be measured in GABA-ergic postsynapses. To this end, EGFP- and mCherry-
gephyrin were co-expressed in hippocampal rat neurons which were stained with an 
antibody directed against the γ2 subunit of the GABAA-receptor. γ2 subunit-containing 
GABAA-receptors do not show extra-synaptic localisation so that they can be used to 
distinguish synaptic and extra-synaptic gephyrin clusters. The signal from γ2 subunit-
containing GABAA-receptors was used to create an optical mask that was used to 
exclude extra-synaptic gephyrin clusters from the analysis. The results show that by 
combining the gephyrin clustering assay with markers of inhibitory postsynapses, 
gephyrin clustering can be measured at identified inhibitory postsynapses. As 
observed in HEK293, cortical neurons treated with rapamycin show an increase in 
FRET efficiencies by 67 % from 3.7 % (SD: 2.3 %) to 6.2 % (SD: 2.2 %). Since there 
is no ectopically expressed mTOR present in these neurons, gephyrin must have 
interacted with endogenous mTORC1 which was subsequently inhibited by the 











5.1 FRET-based mTORC1 and mTORC2 activity assays 
mTOR is a serine/threonine kinase that forms two functionally and structurally distinct 
complexes, mTORC1 and mTORC2. mTORC1 regulates mRNA translation, lipid 
biosynthesis and cellular growth, while mTORC2 regulates cytoskeletal 
rearrangements and cellular survival. 
During activation of mTORC1, mTOR is phosphorylated at serin 2448 by S6K1. This 
phosphorylation is a positive feedback loop that keeps mTORC1 activated by its 
downstream target, which sustains mTORC1 activity. It serves as a marker of active 
mTORC1 in the optical assay presented here.  
Active mTORC2 phosphorylates Akt at S473. This phosphorylation event is executed 
exclusively by mTORC2 and was therefore used as marker in the mTORC2 activity 
assay presented here. 
Phosphorylation events are fast post-translational modifications that have the 
capacity to modulate the signalling properties of molecules. They can be assayed by 
phosphorylation-specific antibodies. 
In this study, two FRET-based phosphorylation sensors were established that allow 
the quantification of endogenous mTORC1 and mTORC2 activity at the single cell 
level. Antibodies might exhibit unspecific binding, which could disguise a 
physiological effect and result in miss-interpretation.  
The major challeng in creating these assays, was the choice of the right antibodies. 
In this case it was even more difficult because 'good' antibodies were only available 
from rabbit. This problem is more frequent than expected: the search engine 
www.biocompare.com will find a total number of 1,742,975 antibodies generated in 
rabbit, but only 709,700 antibodies generated in mouse. Having to use two antibodies 
from the same species is therefore a frequent obstacle for researchers. 
The use of two antibodies from the same species comes with the problem of high 
cross-reactivity (Figure 8). In the present study problems caused by cross-reactivity 
could in part be eased by the use of a monovalent blocking antibody. Monovalent 
Fab fragments reduced the measured standard deviations by up to 50 %, which 
improved the accuracy of the assays (Figure 10). 
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Antigen trapping was identified as the major source of cross-reactivity when using 
two antibodies from the same species (Figure 15). Strategies to overcome this 
problem included blocking of unsaturated antigen binding domains by monovalent 
Fab fragments or the use of blocking peptides but all of these strategies were 
dropped due to practical issues that come along with the use of additional antibodies, 
like epitope loss due to extensive washing, time consumption of repeated antibody 
incubations and steric problems.  
We identified the use of fluorescently labelled, monovalent Fab fragments as 
secondary antibodies to be the only practical way to solve this problem. 
 
5.2 FRET optimisations 
In time correlated single photon counting, even small differences in FRET efficiencies 
can be resolved, as long as there are enough photons to ensure a proper fitting of 
the fluorescence lifetime data. This was ensured by replacing Cy3, which exhibits a 
comparably low brightness and high bleaching susceptibility, with a brighter and 
more photostabile fluorophore ATTO 532. In combination with an improved FRET-
partner, like ATTO 580Q, the FRET efficiency was maximized (Figures 11 and 12). 
The Förster distance is larger between fluorophores with longer emission 
wavelengths as the overlap integral of donor emission and acceptor absorption 
factors in the wavelength by the power of 4 (see section 1.7.1). It is therefore 
beneficial to choose dyes in the 500-600 nm or the 600-700 nm spectral range. For 
practical reasons, the donor fluorophore should be in the visible range. Therefore the 
500-600 nm spectral range was chosen as the donor. 
The present study focused on dyes from the company ATTO-TEC (Berlin, Germany) 
as the most detailed information relevant for FRET and TCSPC FLIM are available 
for these dyes. The Förster distance for every combination of two ATTO-TEC dyes, 
bleaching curves, absorption and emission spectra, fluorescence quantum yields and 
other valuable data are available. 
ATTO 532 in combination with ATTO 580Q has a calculated Förster distance of 67 Å. 
In contrast, Cy3 and Cy5 have a Förster distance of 54 Å, an improvement of 24 %.  
The imaging set up used in the present study is equipped with a 532 nm pulsed laser 
diode. Suitable dyes for this excitation are ATTO 532 and ATTO 550. A direct 
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comparison of ATTO 532 and ATTO 550 with Cy3 shows improvements in terms of 
bleaching, quantum yield and fluorescence lifetime. ATTO 550 is slightly superior in 
terms of absorption but ATTO 532 has the better in fluorescence quantum yield and 
the longer lifetime. However, both dyes are clearly more photostabile than Cy3, 
which is the most important improvement. 
The assay was constructed with the aim of combining it with molecular markers of 
cellular identity. Therefore, the dark fluorescence quencher ATTO 580Q was used as 
an acceptor for FRET. 
In terms of FRET, the assay as it currently is can be considered optimised. There are 
only few adjustments left like increasing the labeling density (currently 0.97 and 1.17 
labels per Fab fragment) of the Fab fragments. But this must be reviewed carefully 
because over-labelling might interfere with the affinity due to blocking of the antigen 
binding domain or with antibody solubility. ATTO 580Q for instance is very 
hydrophobic. 
 
5.3 The mTORC1 assay 
After antigen trapping was excluded by the use of monovalent Fab fragments, the 
primary antibodies were evaluated in an iterative process. In Figure 15 it was shown 
that both antibodies have different staining patterns. A prominent nuclear signal was 
observed with the abcam antibody, while the 7C10 showed a granular staining 
pattern. In the FRET assay, both antibodies showed moderate FRET efficiencies. 
Rapamycin treatment revealed that the high FRET efficiencies in the nucleus were 
probably due to cross-reactivity. 
 The experiment that compared the IHC-specific antibody against the XP 
demonstrated how cross-reactivity hampers the dynamic range of the assay. The 
IHC-specific showed mean FRET efficiency nearly twice as high as the XP. However, 
the high residual FRET under rapamycin conditions of 6 % left a true dynamic range 
of only 3 %, combined with a wider standard deviation due to higher variability. The 
XP antibody was therefore considered superior, despite the fact that the measured 
FRET efficiencies were rather low (Figures 16 and 17).  
Another marker of mTORC1 activity that was tried out here was the phosphorylation 




5.4 mTORC2 assay 
The mTORC2 assay designed was based on the principles of the mTORC1 assay. 
The measured FRET efficiencies reflected changes in the biological substrate. The 
assay showed that inhibition of upstream activator of the Akt pathway lead to a 
complete abrogation of phosphorylation, while insulin increased Akt phosphorylation 
(Figure 20). 
The effect of chronic rapamycin treatment on mTOC2 activity was tested in HEK293 
cells (Figure 21). Chronic treatment with rapamycin induced partial disruption of 
mTORC2 in a previous report (Sarbassov et al., 2006). The disruption of mTORC2 
renders cells insensitive to insulin. In fact, rapamycin induced insulin resistance is the 
major obstacle that has prevented the use of rapamycin in the clinical therapy of 
cancer, neurodegenerative disorders, cardiovascular disease and other age-related 
diseases. The data presented here shows that mTORC2 is resistant to chronic 
rapamycin treatment in HEK293 cells. Instead, mTORC2 signalling is increased by 
chronic rapamycin exposure. This increase may be due to a negative feedback 
mechanism downstream of S6K1. Active S6K1 phosphorylates IRS and thereby 
primes it for proteasomal degradation. This way S6K1 activity limits the activation of 
mTORC2. Rapamycin disrupts this feedback mechanism, leading to an accumulation 
of IRS which fuels the activation path of mTORC2.  
In 2012, Lamming and colleagues showed that rapamycin-induced insulin resistance 
was mediated rapamycin-sensitive mTORC2. The mechanism underlying this 
phenomenon was described by Schreiber and colleagues (2015). They identified the 
ratio of FKBP12 to FKBP51 as the determining factor for mTORC2 rapamycin 
resistance. Cells with a low ratio like HELA or HEK293 are rapamycin insensitive 
while cells with a high ratio like PC3 or C2C12 are rapamycin sensitive.  
 
5.5 Compromised mTORC1 and mTORC2 signalling in Rett 
syndrome. 
The mTORC1- and mTORC2 activity assays consistently reported reduced mTORC1 
and mTORC2 activities in neuronal cells derived from MeCP2-KO mice. The reduced 
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mTORC1 activity seemed to be restricted to neurons while the reduced mTORC2 
activity was observed in all neuronal cell types (Figure 18 and 22). 
The reduced activity of mTORC1 is in agreement with a report from Ricchiardi and 
colleagues (2011) that showed reduced activation of S6K1 in brain lysates of 
MeCP2-KO mice. 
The observed cell-type specific reduction of mTORC1 activity awaits confirmation by 
multiplexing the current FRET assay with markers of neuronal identity. This can be 
done as the assay was designed with application this in mind. As the acceptor is a 
quencher, it allows the re-use of the acceptor channel for markers of neuronal 
identity. These could be NeuN, a neuron marker. Moreover, excitatory neurons can 
be identified by vesicular glutamate transporter 1 or 2, while inhibitory neurons can 
be identified by vesicular inhibitory amino acid transporter or glutamate 
decarboxylase 65. 
A genetic link between MeCP2 and mTOR signalling was elucidated very recently. 
Tsujimura and colleagues (2015), describe the interaction between MeCP2 and the 
microRNA microprocessor drosha complex. This interaction regulates the processing 
of specific miRNA-199a which targets Hif1α, Sirt1 and Pde4d. These genes code 
inhibitory factors of the mTOR pathway, HIF1α, SIRT1 and PDE4D, which are 
upregulated in the brain of MeCP2-KO mice. Loss of miR-199a results in decreased 
mTOR activity in the brain and recapitulated RTT phenotypes in vivo. Vice versa, 
expression of miR-199a rescues neuronal abnormalities caused by the loss of 
MeCP2. 
MeCP2-KO also shows reduced BDNF expression. BDNF is known to sustain 
mTORC1 signalling by activating the TrkB receptor/Akt/mTOR signalling axis in 
neurons. MeCP2-KO mice show reduced expression, transport and secretion of 
BDNF. Bdnf-KO mice recapitulate many phenotypes observed in the MeCP2-KO 
mice. 
Reduced activation of TrkB may also explain reduced mTORC2 activity since this is a 
downstream event. This might represent a positive feedback mechanism, missing in 
MeCP2-KO mice.  
During its activation, Akt is recruited to the plasma membrane where it is 
phosphorylated at threonine 308 by PDK1. This phosphorylation is a pre-requisite for 
the mTORC2-dependent phosphorylation of Akt at S473. Since the activation 
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process of mTORC2 is unknown, it is not clear if the reduced S473 phosphorylation 
is due to a reduced mTORC2 activity or due to the reduced availability Akt 
phosphorylated at T308. mTORC2 might be active, but missing a substrate to 
phosphorylate. This could be interpreted incorrectly as a reduced mTORC2 activity. 
A more direct readout of mTORC2 activity may be the mTOR-Rictor interaction which 
was tried but did not yield any dynamic changes in FRET efficiencies.  
Other tested parameters included the interaction between mTORC2 and the 
TSC1/TSC2 complex, the phosphorylation of tuberin at S939 or T1462, and the 
phosphorylation of downstream target PKC alpha at S657, with similar results. 
 
5.6 mTOR-gephyrin interaction 
In this study the interaction between EGFP-mTOR and mCherry-gephyrin was 
observed in HEK293 cells (Figure 23). It was found that the interaction was 
dependent on active mTOR within mTORC1, which could be disrupted by rapamycin 
or mutation of S270 within gephyrin (Figure 24).  
The little amount of literature on mTOR-gephyrin interaction is contradictory (Sabatini 
et al., 1999; Wuchter et al., 2012). The mTOR-gephyrin interaction was first 
described by Sabatini and colleagues (1999). Gephyrin was found to interact with 
mTOR's gephyrin binding domain (GDB), a stretch of amino acids that show 45 % 
sequence identity with the β-loop of glycine receptor. Mutations in the GDB disrupted 
the interaction with gephyrin and mTOR failed to activate S6K and 4E-BP1. The data 
suggests that gephyrin binds to active mTOR within mTORC1 and that this 
interaction is necessary for proper induction of protein-translation. 
The data presented here is in line with this study and confirms the interaction of 
gephyrin with active mTORC1. 
In contrast, Wuchter and colleagues described the exact opposite mechanism. They 
find that in neurons, gephyrin binds to inactive mTOR and that the activation of 
mTORC1 by BDNF, releases gephyrin from mTOR and allows for it to cluster. The 
authors show that mTORC1 activation increases gephyrin cluster density while 
mTORC1 inhibition decreases gephyrin cluster density. On the functional level, 
mTORC1 inhibition reduced GABAergic inhibition within the neuronal network, which 
resembled the effect of GABAA receptor inhibition.  
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A potential reason for this discrepancy might be the overexpression of mTOR and 
gephyrin. The resulting unnaturally high concentrations of both proteins might induce 
the observed interaction. 
Nevertheless, it should be tested if the interaction between mTOR and gephyrin can 
be observed in neurons as well. 
The inhibition of endogenous mTORC1 in primary cortical neurons increased 
gephyrin clustering as measured with the gephyrin trimerisation assay (Figure 29). 
This suggests that gephyrin clustering was impeded by the interaction with 
endogenous active mTORC1 and that mTORC1 inhibition enabled gephyrin 
clustering. This experiment is in line with the observations made here and with 
Sabatini's data. It suggests that endogenous active mTORC1 interacts with gephyrin 
to negatively regulate it's clustering in primary neurons.  
The mTOR-gephyrin interaction assay was used to find gephyrin-mutants that exhibit 
an altered interaction with mTOR. Serine 270 was identified as an important 
determinant of this interaction. The regulation of the mTOR-gephyrin interaction by 
phosphorylation within gephyrin represents an intriguing regulatory mechanism. It 
would allow for a fast and localized protein translation at the inhibitory postsynapse. It 
would be interesting to know, which clustering-state of gephyrin is preferred by 
mTOR to interact with. To this end, the mTOR-gephyrin interaction should be 
analysed for the clustering impaired mutants of gephyrin. 
Gephyrin S270 was described to be phosphorylated by GSK-3β and CDK5 
(Tyagarajan et al., 2011; Kuhse et al., 2012). The alanine exchange mutation 
resulted in the formation of more and larger gephyrin clusters accompanied by 
increased amplitude and frequency of mIPSCs. GSK-3β activity is negatively 
regulated by Akt activity. Under culture conditions, growth factors and cytokines are 
provided in excess and Akt signalling is close to its maximum. The activity of GSK-3β 
should therefore be close to its minimum and hence gephyrin should be 
unphosphorylated. However, the S270A mutation had a substantial effect on 
gephyrin clustering. It is therefore likely that CDK5 primarily exerts phosphorylation at 
S270A under culture conditions.  
The inhibition of CDK5 reduces the stability of gephyrin clusters as well as GABAA 
receptor clusters (Kalbouneh et al., 2014). This finding points towards major 
discrepancy in the effect of GSK-3β and CDK5 at S270. The inhibition of GSK-3β as 
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well as the expression of S270A increased gephyrin cluster size (Tyagarayan et al., 
2011), but the pharmacological inhibition of CDK5 decreases the size of gephyrin 
and GABAA receptor clusters. One possible explanation could be that other kinases 
phosphorylate the regulatory domain of gephyrin, and that different combinatorial 
patterns of phosphorylation have divergent functional consequences. 
 
5.7 Gephyrin clustering measured by FRET 
5.7.1 Gephyrin trimerisation 
In order to analyse the clustering of gephyrin, N-terminal fusion constructs of EGFP-
gephyrin and mCherry-gephyrin were co-expressed in HEK293. The trimerisation of 
full length gephyrin could be measured by FRET between EGFP and mCherry 
(Figure 25). 
The co-expression of CB2 or NL2, recruited gephyrin to the plasma membrane and 
promoted trimer formation (Figure 27), which resulted in markedly increased FRET 
efficiencies. Collybistin seemed to be more efficient in promoting gephyrin 
trimerisation. Also rapamycin induced gephyrin trimerisation in HEK293 as well as in 
primary cortical neurons (Figure 29).  
 
5.7.2 Gephyrin trimerisation and dimerization mutants 
The expression of dimerisation and trimerisation impaired mutants of gephyrin 
allowed structural insights into gephyrin clustering in HEK293 cells. The trimerisation 
impaired mutant 4×R reduced the trimerisation by 71 % which was expected. 
Unexpectedly the dimerisation impaired mutant RER was also efficiently impaired in 
trimerisation, by remarkable 57 %. This was surprising because of structural data. 
Nevertheless, the regulatory C-domain of gephyrin might allow for a direct interaction 
of the G- and the E-domain even though a direct interaction has not been described 
yet. It is more likely that gephyrin monomers, trimers and the hexagonal lattice form 
three interdependent pools that are in a state of dynamic equilibrium (Figure 26). In 
this model, all three pools communicate via concentration. A very high concentration 
of monomers would promote the trimerisation process. Vice versa, the massive 
depolymerisation of the lattice into trimers would also promote the disintegration of 
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trimers into monomers. This was observed in the dimerisation mutant. The 
dimerisation impaired mutant showed markedly reduced trimerisation, which might be 
explained by the fact that the formation of the lattice is prohibited and the expected 
high timer concentration might cause the disintegration of trimers into monomers.  
 
5.7.3 Gephyrin dimerisation 
C-terminal fusion constructs of full length gephyrin with either mTurquoise or EYFP 
were used to quantify the dimerisation of gephyrin's E-domains in HEK293 cells. Like 
in the trimerisation assay collybistin and neuroligin 2 are potent activators of the 
dimerisation (Figure 29). This is in line with the previous assumption of inter pools of 
gephyrin clustering states that communicate in a dynamic equilibrium. A massive 
increase in trimer-formation would also drive the dimerisation of the E-domains. 
Unfortunately, our assay as it was designed here was not able to distinguish between 
the hexagonal lattice model and the stacked trimer model (Figure 1). In both models 
the E-domains as well as the G-domains interact in a way that allows for FRET to 
occur. The analysis of 4×R and the RER mutant in the dimerisation assay could help 
to elucidate the clustering process further. Also the measurement of diffusion 
constants of gephyrin clustering mutants with fluorescence correlation spectroscopy 
could help to answer the final questions about the correct clustering model.  
Both gephyrin assays, for the first time allow a quantification of the oligomerisation 
process of full length gephyrin at the inhibitory post-synapse. This represents a clear 
improvement over the so far used analysis of purified single domains that are 
expressed in heterologous expression systems like E.coli. Bacterial expression 
systems do not possess the enzymatic machinery to exert post-translational 
modifications at eukaryotic proteins. The assays designed here represent new optical 
tool to analyse effects of post-translational modifications on gephyrin clustering.  
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6 Conclusions and Future Perspectives 
 
In this study antibody-based FRET assays of mTORC1 and mTORC2 activity were 
established and evaluated. They have shown to work on the single cell level and 
across species. They provide qualitative and quantitative information on mTORC1 
and mTORC2 activity and are designed to be combined with molecular markers of 
cellular identity or of sub-cellular structures.  
They were used to confirm the reduced mTORC1 activity in neurons of MeCP2-KO 
mice, a mouse model of the Rett syndrome. These experiments suggested a neuron-
specific reduction in mTORC1 signalling. This finding needs confirmation by 
multiplexing the mTORC1 assay with neuronal markers. The identification of affected 
neuronal subtypes might help to find therapeutic strategies to ease symptoms of Rett 
syndrome in the future. 
The interaction of mTOR with gephyrin, a molecular organiser of inhibitory 
postsynapses, represents a potential mechanism for inhibitory synapse formation 
and plasticity. To further elucidate the details of this interaction a FRET assay was 
established that confirmed the interaction in HEK293 cells. Mutations of gephyrin that 
corrupt the interaction were searched and S270 was identified as an important 
determinant of this interaction. 
In the future the mTOR-gephyrin interaction and the consequences of its failure 
should be confirmed at the inhibitory post-synapse. Moreover the meaning of this 
interaction in the context of synapse formation and plasticity should be elucidated. 
The functions of gephyrin at the inhibitory postsynapse include the organisation of 
inhibitory neurotransmitter receptors and the integration of neuron-specific signalling. 
The organisation of neurotransmitters requires gephyrin to build a 2 dimensional 
network underneath the synaptic membrane. Gephyrin clustering assays were 
established that allowed the quantification of that process. In the future these assay 
can be used to determine how clustering is connected to the signalling function of 
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